

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Ann-Marc Koss Examiner #: 78972 Date: 6/4/02
 Art Unit: 1751 Phone Number 305-3176 Serial Number: 091931914
 Mail Box and Bldg/Room Location: 9830 CP3 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic; and describe as specifically as possible the subject matter to be searched. Include the elected species or structures; keywords; synonyms, acronyms, and registry numbers; and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention:

Inventors (please provide full names): Nguyen, Nghi Van ; Cannell, David

Earliest Priority Filing Date: 8/20/2001

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search compound of formula 1 as defined
in claim 1.

Thanks

STAFF USE ONLY

Searcher: K. Fullenkamp

Searcher Phone #: 305-3176

Searcher Location: CP3

Date Searcher Picked Up: 6/4/02

Date Completed: 6/14/02

Searcher Prep/Review Time: 20

Clerical Prep Time:

Online Time: 35

Type of Search

NA Sequence (#)

Vendors and cost where applicable

STN

AA Sequence (#)

Dialog

Structure (#)

Questel/Orbit

Bibliographic

Dr. Link

Litigation

Lexis/Nexis

Fulltext

Sequence Systems

Patent Family

WWW/Internet

Other

Other (specify)

=> file reg
FILE 'REGISTRY' ENTERED AT 12:03:34 ON 14 JUN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 12 JUN 2002 HIGHEST RN 429617-62-9
DICTIONARY FILE UPDATES: 12 JUN 2002 HIGHEST RN 429617-62-9

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> file hcplus
FILE 'HCPLUS' ENTERED AT 12:03:38 ON 14 JUN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 14 Jun 2002 VOL 136 ISS 24
FILE LAST UPDATED: 12 Jun 2002 (20020612/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

CAS roles have been modified effective December 16, 2001. Please
check your SDI profiles to see if they need to be revised. For
information on CAS roles, enter HELP ROLES at an arrow prompt or use
the CAS Roles thesaurus (/RL field) in this file.

=> d que
L4 4 SEA FILE=REGISTRY ABB=ON CALCIUM HYDROXIDE/CN OR BARIUM
HYDROXIDE/CN OR MAGNESIUM HYDROXIDE/CN OR ALUMINUM HYDROXIDE/CN
L5 1 SEA FILE=REGISTRY ABB=ON "CUPRIC HYDROXIDE"/CN
L6 6 SEA FILE=REGISTRY ABB=ON STRONTIUM HYDROXIDE/CN OR MOLYBDENUM
HYDROXIDE/CN OR MANGANESE HYDROXIDE/CN OR ZINC HYDROXIDE/CN OR
COBALT HYDROXIDE/CN
L7 11 SEA FILE=REGISTRY ABB=ON (L4 OR L5 OR L6)
L8 1515 SEA FILE=REGISTRY ABB=ON ((CA OR BA OR MG OR AL OR CU OR SR
OR MO OR MN OR ZN OR CO)(L)O(L)H)/ELS(L)3/ELC.SUB

hydroxides
claim 3

L9	48595 SEA FILE=HCAPLUS ABB=ON	L7
L10	100 SEA FILE=HCAPLUS ABB=ON	L9 AND (HAIR OR KERAT?)
L11	2 SEA FILE=HCAPLUS ABB=ON	L10 AND LANTHION?
L13	12 SEA FILE=HCAPLUS ABB=ON	L10 AND RELAX?
L15	61496 SEA FILE=HCAPLUS ABB=ON	L8
L16	112 SEA FILE=HCAPLUS ABB=ON	L15 AND (HAIR OR KERAT?)
L17	13 SEA FILE=HCAPLUS ABB=ON	L16 AND (RELAX? OR LANTHIO?)
L18	13 SEA FILE=HCAPLUS ABB=ON	L11 OR L13 OR L17
L19	112 SEA FILE=HCAPLUS ABB=ON	L10 OR L16
L20	55 SEA FILE=HCAPLUS ABB=ON	L19 AND (COMPOSITION? OR COMPNS)
L21	34 SEA FILE=HCAPLUS ABB=ON	L20 AND COSMETIC?/SC, SX
L22	40 SEA FILE=HCAPLUS ABB=ON	L20 AND (HAIR OR KERAT? (3A) FIBER?)
L23	30 SEA FILE=HCAPLUS ABB=ON	L21 AND L22
L24	11 SEA FILE=HCAPLUS ABB=ON	L23 AND (RELAX? OR RELEAS? OR LANTH?)
<u>L27</u>	17 SEA FILE=HCAPLUS ABB=ON	L21 AND HYDROXIDES/IT
L28	24 SEA FILE=HCAPLUS ABB=ON	L18 OR L24 OR L27
L29	4 SEA FILE=HCAPLUS ABB=ON	L20 AND COMPLEX?
L30	27 SEA FILE=HCAPLUS ABB=ON	L28 OR L29

=> d 130 1-27 all hitstr

L30 ANSWER 1 OF 27 HCAPLUS COPYRIGHT 2002 ACS
 AN 2002:236839 HCAPLUS
 DN 136:252259
 TI **Composition**, packaged in an aerosol device, comprising alumina nanoparticles
 IN Nocerino, Cecile; Giroud, Franck; Sturla, Jean-Michel
 PA L'Oreal, Fr.
 SO Eur. Pat. Appl., 7 pp.
 CODEN: EPXXDW
 DT Patent
 LA French
 IC ICM A61K007-11
 CC 62-3 (Essential Oils and **Cosmetics**)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1190701	A1	20020327	EP 2001-402397	20010919
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	FR 2814067	A1	20020322	FR 2000-11991	20000920
	JP 2002145735	A2	20020522	JP 2001-282664	20010918
	US 2002037256	A1	20020328	US 2001-955299	20010919
PRAI	FR 2000-11991	A	20000920		
AB	A hair aerosol contains a liq. phase comprising aluminum hydroxide nanopartilces having av. size 2-200 nm, and a propellant. A hair aerosol contained aluminum oxide nanoparticle having an av. size 13 nm 0.3, water 2.7, ethanol 32, and di-Me ether 65%.				
ST	cosmetics hair aerosol alumina nanoparticle propellant				
IT	Alkanes, biological studies RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (C3-5; compn. , packaged in aerosol device, comprising alumina nanoparticles)				
IT	Alcohols, uses RL: NUU (Other use, unclassified); USES (Uses) (C3-5; compn. , packaged in aerosol device, comprising alumina nanoparticles)				
IT	Lactams				

27 CA references from the hydroxides (claim3) and utility. The complex agent (claim1, formula I) is too broad to search.

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(N-vinyl, polymers; **compn.**, packaged in aerosol device,
comprising alumina nanoparticles)

IT Cosmetics
(aerosols; **compn.**, packaged in aerosol device, comprising
alumina nanoparticles)

IT Fats and Glyceridic oils, biological studies
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(animal; **compn.**, packaged in aerosol device, comprising
alumina nanoparticles)

IT Adhesives
Antifoaming agents
Antiperspirants
Dyes
Nanoparticles
Perfumes
Pigments, nonbiological
Preservatives
Propellants (sprays and foams)
Reducing agents
Solvents
Sunscreens
Surfactants
Sweetening agents
Thickening agents
(**compn.**, packaged in aerosol device, comprising alumina
nanoparticles)

IT Oxides (inorganic), biological studies
Paraffin oils
Polymers, biological studies
Polysiloxanes, biological studies
Proteins
Thiols (organic), biological studies
Vitamins
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(**compn.**, packaged in aerosol device, comprising alumina
nanoparticles)

IT Acids, uses
RL: NUU (Other use, unclassified); USES (Uses)
(**compn.**, packaged in aerosol device, comprising alumina
nanoparticles)

IT Alkali metal **hydroxides**
RL: NUU (Other use, unclassified); USES (Uses)
(**compn.**, packaged in aerosol device, comprising alumina
nanoparticles)

IT Alcohols, biological studies
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(polyhydric; **compn.**, packaged in aerosol device, comprising
alumina nanoparticles)

IT Fats and Glyceridic oils, biological studies
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(vegetable; **compn.**, packaged in aerosol device, comprising
alumina nanoparticles)

IT 67-64-1, Acetone, biological studies 75-37-6, 1,1-Difluoroethane
115-10-6, Dimethylether 1303-86-2, Boron oxide, biological studies
1344-28-1, Alumina, biological studies 63957-70-0, Boehmite
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(**compn.**, packaged in aerosol device, comprising alumina
nanoparticles)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; PATENT ABSTRACTS OF JAPAN 1983, V7(205), PC-185
 (2) Anon; PATENT ABSTRACTS OF JAPAN 2001, V2000(11)
 (3) Osaka Ship Building Co; JP 2000212051 A 2000 HCPLUS
 (4) Touyou Aerosol Kogyo Kk; JP 58103301 A 1983 HCPLUS

IT 63957-70-0, Boehmite

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
 (compn., packaged in aerosol device, comprising alumina
 nanoparticles)

RN 63957-70-0 HCPLUS

CN Boehmite (Al₂O₃.xH₂O) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L30 ANSWER 2 OF 27 HCPLUS COPYRIGHT 2002 ACS

AN 2002:236838 HCPLUS

DN 136:267894

TI Cosmetic **compn.** comprising alumina nanoparticles and a
 fixing polymer

IN Nocerino, Cecile; Giroud, Franck; Sturlag, Jean-Michel

PA L'Oreal, Fr.

SO Eur. Pat. Appl., 14 pp.

CODEN: EPXXDW

DT Patent

LA French

IC ICM A61K007-11

CC 62-3 (Essential Oils and **Cosmetics**)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1190700	A1	20020327	EP 2001-402396	20010919
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	FR 2814068	A1	20020322	FR 2000-11992	20000920
PRAI	FR 2000-11992	A	20000920		
AB	Cosmetic compn. comprising alumina nanoparticles having av. size .1toreq.25 nm and a fixing polymer are disclosed. A hair prepn. contained aluminum oxide (av. particle size = 13 nm) 0.3, polyvinylpyrrolidone 2, ethanol 32.7, and di-Me ether 65%.				
ST	hair cosmetic alumina nanoparticle fixing polymer				
IT	Alcohols, uses RL: NUU (Other use, unclassified); USES (Uses) (C1-4; cosmetic compn. comprising alumina nanoparticles and fixing polymer)				
IT	Cosmetics (aerosols; cosmetic compn. comprising alumina nanoparticles and fixing polymer)				
IT	Fats and Glyceridic oils, biological studies RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (animal; cosmetic compn. comprising alumina nanoparticles and fixing polymer)				
IT	Adhesives Antifoaming agents Antiperspirants Dyes Nanoparticles Perfumes Pigments, nonbiological Preservatives Reducing agents				

Solvents
Sunscreens
Surfactants
Thickening agents
(cosmetic compn. comprising alumina nanoparticles and fixing polymer)

IT Oxides (inorganic), biological studies
Paraffin oils
Polymers, biological studies
Polysiloxanes, biological studies
Proteins
Thiols (organic), biological studies
Vitamins
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(cosmetic compn. comprising alumina nanoparticles and fixing polymer)

IT Acids, uses
RL: NUU (Other use, unclassified); USES (Uses)
(cosmetic compn. comprising alumina nanoparticles and fixing polymer)

IT Alkali metal hydroxides
RL: NUU (Other use, unclassified); USES (Uses)
(cosmetic compn. comprising alumina nanoparticles and fixing polymer)

IT Cosmetics
(gels; cosmetic compn. comprising alumina nanoparticles and fixing polymer)

IT Alcohols, uses
RL: NUU (Other use, unclassified); USES (Uses)
(polyhydric; cosmetic compn. comprising alumina nanoparticles and fixing polymer)

IT Fats and Glyceridic oils, biological studies
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(vegetable; cosmetic compn. comprising alumina nanoparticles and fixing polymer)

IT 1303-86-2, Boron oxide, biological studies 1344-28-1, Alumina, biological studies 9003-39-8, Polyvinylpyrrolidone 25086-89-9, Vinyl acetate-vinylpyrrolidone copolymer 25189-83-7, Polyvinylcaprolactam 26124-25-4, Vinyl acetate-vinyl propionate-vinylpyrrolidone copolymer 63957-70-0, Boehmite
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(cosmetic compn. comprising alumina nanoparticles and fixing polymer)

IT 64-17-5, Ethanol, uses 67-64-1, Acetone, uses
RL: NUU (Other use, unclassified); USES (Uses)
(cosmetic compn. comprising alumina nanoparticles and fixing polymer)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE
(1) Anon; PATENT ABSTRACTS OF JAPAN 2001, V2000(11)
(2) Osaka Ship Building Co; JP 2000212051 A 2000 HCPLUS
(3) Unilever; WO 0130310 A 2001 HCPLUS

IT 63957-70-0, Boehmite
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(cosmetic compn. comprising alumina nanoparticles and fixing polymer)

RN 63957-70-0 HCPLUS

CN Boehmite (Al₂O₃.xH₂O) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L30 ANSWER 3 OF 27 HCAPLUS COPYRIGHT 2002 ACS
 AN 2001:780648 HCAPLUS
 DN 135:335147
 TI Polymer-based injectable sustained release pharmaceutical compositions for peptide and protein drugs
 IN Lee, Hee-yong; Lee, Hye-suk; Kim, Jung-soo; Kim, Sang-beom; Lee, Ji-suk;
 Choi, Ho-il; Chang, Seung-gu
 PA Peptron Inc., S. Korea
 SO PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K009-22
 CC 63-6 (Pharmaceuticals)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001078687	A1	20011025	WO 2001-KR462	20010322
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1187602	A1	20020320	EP 2001-917893	20010322
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	KR 2000-20484	A	20000418		
	KR 2000-49344	A	20000824		
	WO 2001-KR462	W	20010322		

AB Controlled and sustained release injectable pharmaceutical compns. for a biopharmaceutical, such as peptides and proteins are described. Processes for prepn. of an injectable sustained release compn. comprises (i) a step of prep. biodegradable porous microspheres having accessible ionic functional groups, (ii) a step of encapsulating a biopharmaceutical into the microspheres through ionic interaction by suspending or equilibrating the microspheres in a soln. contg. the biopharmaceutical, and (iii) a step of recovering and freeze-drying the biopharmaceutical-incorporated microspheres. For example, microspheres were prep. by water/oil/water double emulsion solvent evapn. method using a hydrophilic 50:50 PLGA polymer (RG 502H), which contains free carboxy end groups. Deionized water (800 mL) was added to 1 g of PLGA polymer dissolved in 2 mL of methylene chloride and emulsified by sonication for 30 s using a probe type ultrasonic generator. This primary emulsion was dispersed into 200 mL of deionized water contg. 0.5% polyvinyl alc. (wt./vol.) in a vessel which connected to a const. temp. controller and mixed well by stirring for 15 min at 2500 rpm, 25.degree. using a mixer. After mixing for another 15 min at 1500 rpm, 25.degree., temp. of continuous phase was increased to 40.degree. to evap. methylene chloride. After 1 h stirring at 40.degree., 1500 rpm, temp. was decreased to 25.degree.. The hardened microspheres were collected by centrifugation and washed twice with 200 mL of deionized water, and then freeze-dried. The microspheres obtained were used for incorporation of protein drugs, i.e., ovalbumin, bovine serum albumin, human growth hormone, RNase A, or lysozyme through ionic interaction by simply soaking and equilibrating the microspheres into a buffer soln. having an appropriate concn. of protein.

ST peptide protein polymer encapsulation controlled release microsphere;
sustained release microsphere peptide protein injection

IT Proteins, specific or class
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(A; prepn. of polymer-based injectable sustained-release microspheres
for peptide and protein drugs)

IT Proteins, specific or class
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C-reactive; prepn. of polymer-based injectable sustained-release
microspheres for peptide and protein drugs)

IT Proteins, specific or class
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C; prepn. of polymer-based injectable sustained-release microspheres
for peptide and protein drugs)

IT Apolipoproteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(E; prepn. of polymer-based injectable sustained-release microspheres
for peptide and protein drugs)

IT Acids, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(acidifying agents; prepn. of polymer-based injectable
sustained-release microspheres for peptide and protein drugs)

IT Alkali metal hydroxides
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(alkalizing agents; prepn. of polymer-based injectable
sustained-release microspheres for peptide and protein drugs)

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides; prepn. of polymer-based injectable
sustained-release microspheres for peptide and protein drugs)

IT Functional groups
Surfactants
(anionic; prepn. of polymer-based injectable sustained-release
microspheres for peptide and protein drugs)

IT Antibodies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-infective; prepn. of polymer-based injectable sustained-release
microspheres for peptide and protein drugs)

IT Vaccines
(antigens; prepn. of polymer-based injectable sustained-release
microspheres for peptide and protein drugs)

IT Polymers, biological studies
Polyurethanes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biodegradable; prepn. of polymer-based injectable sustained-release
microspheres for peptide and protein drugs)

IT Polyesters, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(caprolactone-based; prepn. of polymer-based injectable
sustained-release microspheres for peptide and protein drugs)

IT Growth factors, animal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cartilage-inducing factor; prepn. of polymer-based injectable
sustained-release microspheres for peptide and protein drugs)

IT Surfactants
(cationic; prepn. of polymer-based injectable sustained-release
microspheres for peptide and protein drugs)

IT Glycoproteins, specific or class

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cytotoxic; prepn. of polymer-based injectable sustained-release
microspheres for peptide and protein drugs)

IT Polyesters, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dilactone-based; prepn. of polymer-based injectable sustained-release
microspheres for peptide and protein drugs)

IT Lymphokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(erythroid-potentiating factors; prepn. of polymer-based injectable
sustained-release microspheres for peptide and protein drugs)

IT B cell (lymphocyte)
T cell (lymphocyte)
(factors regulating; prepn. of polymer-based injectable
sustained-release microspheres for peptide and protein drugs)

IT Polyesters, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glycolide-based; prepn. of polymer-based injectable sustained-release
microspheres for peptide and protein drugs)

IT Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunotherapeutic; prepn. of polymer-based injectable
sustained-release microspheres for peptide and protein drugs)

IT Drug delivery systems
(immunotoxins; prepn. of polymer-based injectable sustained-release
microspheres for peptide and protein drugs)

IT Drug delivery systems
(injections, controlled release; prepn. of polymer-based injectable
sustained-release microspheres for peptide and protein drugs)

IT Drug delivery systems
(injections, sustained release; prepn. of polymer-based injectable
sustained-release microspheres for peptide and protein drugs)

IT Polyesters, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lactide; prepn. of polymer-based injectable sustained-release
microspheres for peptide and protein drugs)

IT Annexins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipomodulin; prepn. of polymer-based injectable sustained-release
microspheres for peptide and protein drugs)

IT Casting process
(low temp.; prepn. of polymer-based injectable sustained-release
microspheres for peptide and protein drugs)

IT Cytokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(macrophage-activating factor; prepn. of polymer-based injectable
sustained-release microspheres for peptide and protein drugs)

IT Encapsulation
(microencapsulation; prepn. of polymer-based injectable
sustained-release microspheres for peptide and protein drugs)

IT Drug delivery systems
(microspheres, controlled-release; prepn. of polymer-based injectable
sustained-release microspheres for peptide and protein drugs)

IT Polyethers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ortho ester group-contg.; prepn. of polymer-based injectable
sustained-release microspheres for peptide and protein drugs)

IT Growth factors, animal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(osteogenic growth factors; prepn. of polymer-based injectable

sustained-release microspheres for peptide and protein drugs)

IT Macrophage
(peptides; prepn. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

IT Functional groups
(phosphoryl group; prepn. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

IT Polyamides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(poly(amino acids); prepn. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

IT Polyesters, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyamide-; prepn. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

IT Polyamides, biological studies
Polyethers, biological studies
Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyester-; prepn. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

IT Polyesters, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyether-; prepn. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

IT Polyesters, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyoxyalkylene-; prepn. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

IT Anti-infective agents
Antibacterial agents
Antiviral agents
Carboxyl group
Cryoprotectants
Evaporation
Fibrinolytics
Freeze drying
Particle size
Phase separation
Pulmonary surfactant
Solvent extraction
(prepn. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

IT Albumins, biological studies
Fibrins
Gelatins, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

IT Annexins
Bone morphogenetic proteins
Caseins, biological studies
Collagens, biological studies
Fibrinogens
Hemoglobins
Interferons
Interleukin 1
Interleukins
Lymphotoxin

Ovalbumin
Platelet-derived growth factors
Polyanhydrides
Polycarbonates, biological studies
Polymer blends
Polysaccharides, biological studies
Proteins, general, biological studies
Transferrins
Transforming growth factors
Tumor necrosis factors
Zeins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

IT Drying
(spray; prepн. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

IT Functional groups
(sulfonyl group; prepн. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

IT Extraction
(supercrit.; prepн. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

IT Antigens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vaccine; prepн. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

IT 9001-99-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(A; prepн. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

IT 50-21-5, Lactic acid, biological studies 77-92-9, Citric acid, biological studies 79-14-1, Glycolic acid, biological studies 87-69-4, Tartaric acid, biological studies 110-17-8, Fumaric acid, biological studies 6915-15-7, Malic acid
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(acidifying agent; prepн. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

IT 102-71-6, Triethanolamine, biological studies 111-42-2, Diethanolamine, biological studies 141-43-5, Monoethanolamine, biological studies 144-55-8, Sodium bicarbonate, biological studies 471-34-1, Calcium carbonate, biological studies 546-93-0, Magnesium carbonate 994-36-5, Sodium citrate 1309-48-4, Magnesium oxide, biological studies 6284-40-8, Meglumine 7778-49-6, Potassium citrate 14987-04-3, Magnesium trisilicate
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkalizing agent; prepн. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

IT 9002-64-6, Parathyroid hormone
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(and inhibitors; prepн. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

IT 1066-33-7, Ammonium bicarbonate
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gas forming agent; prepн. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

IT 9001-12-1, Collagenase 9015-94-5, Renin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; prepn. of polymer-based injectable sustained-release
microspheres for peptide and protein drugs)

IT 105913-11-9, Plasminogen activator
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(kidney; prepn. of polymer-based injectable sustained-release
microspheres for peptide and protein drugs)

IT 64-19-7, Acetic acid, biological studies 111-86-4, Octylamine
124-07-2, Caprylic acid, biological studies 1309-42-8, Magnesium
hydroxide 7647-14-5, Sodium chloride, biological studies 10043-52-4,
Calcium chloride, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(prepn. of polymer-based injectable sustained-release microspheres for
peptide and protein drugs)

IT 121-54-0, Benzethonium chloride 151-21-3, Sodium lauryl sulfate,
biological studies 577-11-7, Docusate sodium 1393-25-5, Secretin
1398-61-4, Chitin 1402-38-6, Oncostatin 8044-71-1, Cetrimide
9001-25-6, Blood-coagulation factor VII 9001-28-9, Factor IX
9001-63-2, Lysozyme 9002-01-1, Streptokinase 9002-60-2,
Adrenocorticotrophic hormone, biological studies 9002-61-3, Human
chorionic gonadotropin 9002-67-9, Luteinizing hormone 9002-68-0,
Follicle stimulating hormone 9002-69-1, Relaxin 9002-71-5,
Thyroid stimulating hormone 9002-72-6, Growth hormone 9002-89-5,
Polyvinyl alcohol 9004-10-8, Insulin, biological studies 9004-53-9,
Dextrin 9004-54-0, Dextran, biological studies 9004-61-9, Hyaluronic
acid 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid
9005-49-6, Heparin, biological studies 9007-12-9, Calcitonin
9007-27-6, Chondroitin 9007-92-5, Glucagon, biological studies
9011-97-6, Cholecystokinin 9012-76-4, Chitosan 9015-71-8,
Corticotropin releasing factor 9034-39-3, Growth hormone releasing
factor 9035-68-1, Proinsulin 9039-53-6, Urokinase 9041-92-3,
.alpha.1-Antitrypsin 9054-89-1, Superoxide dismutase 9056-36-4,
Keratan sulfate 9061-61-4, Nerve growth factor 11096-26-7,
Erythropoietin 15802-18-3D, Cyanoacrylic acid, esters, polymers
24980-41-4, Polycaprolactone 25104-18-1, Poly(L-lysine) 25248-42-4,
Polycaprolactone 25868-59-1 25931-47-9 26009-03-0, Polyglycolide
26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26202-08-4,
Polyglycolide 26680-10-4, Polylactide 26780-50-7, Poly(lactide-co-
glycolide) 31621-87-1, Polydioxanone 34346-01-5, Resomer RG 502H
37221-79-7, Vasoactive intestinal polypeptide 38000-06-5, Poly(L-lysine)
52906-92-0, Motilin 57285-09-3, Inhibin 59392-49-3, Gastric inhibitory
peptide 59763-91-6, Pancreatic polypeptide 61912-98-9, Insulin-like
growth factor 62229-50-9, Epidermal growth factor 62683-29-8, Colony
stimulating factor 67763-96-6, Somatomedin C 77272-10-7, Macrocortin
80043-53-4, Gastrin releasing peptide 82657-92-9, Prourokinase
83652-28-2, Calcitonin gene-related peptide 85637-73-6, Atrial
natriuretic factor 113189-02-9, Antihemophilic factor 139639-23-9,
Tissue plasminogen activator
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of polymer-based injectable sustained-release microspheres for
peptide and protein drugs)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Bodmer; In J Controlled Release 1992, V211-3, P129
(2) Syntex Inc; US 5470582 1995 HCAPLUS

IT 1309-42-8, Magnesium hydroxide

RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(prepn. of polymer-based injectable sustained-release microspheres for peptide and protein drugs)

RN 1309-42-8 HCPLUS
 CN Magnesium hydroxide (Mg(OH)2) (9CI) (CA INDEX NAME)

HO—Mg—OH

L30 ANSWER 4 OF 27 HCPLUS COPYRIGHT 2002 ACS

AN 2001:661220 HCPLUS

DN 135:215751

TI Hair relaxer compositions containing complexing agent activators

IN Van Nguyen, Nghi; Cannell, David W.

PA L'oreal, Fr.

SO PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K007-06

CC 62-3 (Essential Oils and Cosmetics)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064171	A2	20010907	WO 2001-US6338	20010228
	WO 2001064171	A3	20020110		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-516942 A 20000301

AB The present invention provides a compn. for lanthionizing keratin fibers comprising at least 1 multivalent metal hydroxide and at least 1 complexing agent effective for dissocg. one multivalent metal hydroxide in sufficient quantity to effect lanthionization of the keratin fibers. In one embodiment, the complex that is formed between the complexing agent and a metal ion from the multivalent metal hydroxide is sol. in water. thus, a gel was prep'd. from mineral oil 15.0, petrolatum 5.5, Sr(OH)2 octahydrate 18.6, propylene glycol 3.0, acrylates/Ceteth-20 itaconate copolymer 7.0, and water 50.9%. The relaxer gel (6 g) was mixed with a soln. of 1.83 g tetrasodium EDTA in 2 g water and the mixt. was applied to kinky hair. The relaxing efficiency of the strontium/EDTA hair relaxer was found to be in excess of 85%.

ST hair relaxer complexing agent; hydroxide
 EDTA hair relaxer

IT Ion exchangers

(hair relaxer compns. contg.
 complexing agent activators)

IT Amino acids, biological studies
 Crown ethers

Hydroxides (inorganic)

applicants

Silicates, biological studies
Sulfonic acids, biological studies
Zeolite-group minerals
Zeolites (synthetic), biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (hair relaxer compns. contg.
 complexing agent activators)

IT Carboxylic acids, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (hydroxy; hair relaxer compns. contg.
 complexing agent activators)

IT Hair preparations
 (straighteners; hair relaxer compns.
 contg. complexing agent activators)

IT 60-00-4, EDTA, biological studies 67-43-6, Diethylenetriaminepentaacetic acid 77-92-9, Citric acid, biological studies 87-69-4, Tartaric acid, biological studies 93-62-9, N-(2-Hydroxyethyliminodiacetic acid 139-13-9 139-89-9, Trisodium N-(hydroxyethyl)ethylenediaminetriacetate 140-01-2, Pentasodium diethylenetriaminepentaacetate 150-39-0, N-(Hydroxyethyl)ethylenediaminetriacetic acid 1305-62-0, Calcium hydroxide (Ca(OH)2), biological studies 1309-42-8, Magnesium hydroxide 1318-10-1, Analcime 1318-50-9, Epistilbite 1318-63-4, Heulandite 1318-80-5, Laumontite 1318-83-8, Levynite 1318-95-2, Natrolite 1319-20-6, Scolecite 1327-36-2, Aluminosilicate 1763-07-1, Guanidine phosphate 2235-43-0 5064-31-3, Trisodium Nitritotriacetate 6419-19-8, Aminotrimethylenephosphonic acid 6834-92-0, Sodium metasilicate 7408-20-0, Iminodisuccinic acid 7601-54-9, Trisodium phosphate 7778-53-2, Tripotassium phosphate 10006-28-7, Silicic acid (H2SiO3), dipotassium salt 12043-66-2, Mesolite 12173-28-3, Faujasite 12173-98-7, Mordenite 12174-18-4, Phillipsite 12197-41-0, Brewsterite 12251-23-9, Gismondine 12251-32-0, Chabazite 12251-35-3, Gmelinite 12251-39-7, Harmotome 12252-36-7, Edingtonite 12399-54-1, Thomsonite 12446-28-5, Stilbite 17194-00-2, Barium hydroxide (Ba(OH)2)
18480-07-4, Strontium hydroxide (Sr(OH)2) 18933-05-6, Manganese hydroxide (Mn(OH)2) 20427-58-1, Zinc hydroxide (Zn(OH)2) 20427-59-2, Copper hydroxide (Cu(OH)2) 21041-93-0, Cobalt hydroxide (Co(OH)2) 21645-51-2, Aluminum hydroxide (Al(OH)3), biological studies 120070-48-6 126853-99-4, Molybdenum hydroxide 148124-41-8 148124-42-9
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (hair relaxer compns. contg.
 complexing agent activators)

IT 64-02-8, Tetrasodium EDTA 1311-10-0, Strontium hydroxide octahydrate
RL: BUU (Biological use, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
 (hair relaxer compns. contg.
 complexing agent activators)

IT 1305-62-0, Calcium hydroxide (Ca(OH)2), biological studies 1309-42-8, Magnesium hydroxide 17194-00-2, Barium hydroxide (Ba(OH)2) 18480-07-4, Strontium hydroxide (Sr(OH)2) 18933-05-6, Manganese hydroxide (Mn(OH)2) 20427-58-1, Zinc hydroxide (Zn(OH)2) 20427-59-2, Copper hydroxide (Cu(OH)2) 21041-93-0, Cobalt hydroxide (Co(OH)2) 21645-51-2, Aluminum hydroxide (Al(OH)3), biological studies 126853-99-4, Molybdenum hydroxide
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES

(Uses)

(hair relaxer compns. contg.
complexing agent activators)

RN 1305-62-0 HCPLUS

CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)

HO—Ca—OH

RN 1309-42-8 HCPLUS

CN Magnesium hydroxide (Mg(OH)2) (9CI) (CA INDEX NAME)

HO—Mg—OH

RN 17194-00-2 HCPLUS

CN Barium hydroxide (Ba(OH)2) (9CI) (CA INDEX NAME)

HO—Ba—OH

RN 18480-07-4 HCPLUS

CN Strontium hydroxide (Sr(OH)2) (9CI) (CA INDEX NAME)

HO—Sr—OH

RN 18933-05-6 HCPLUS

CN Manganese hydroxide (Mn(OH)2) (8CI, 9CI) (CA INDEX NAME)

HO—Mn—OH

RN 20427-58-1 HCPLUS

CN Zinc hydroxide (Zn(OH)2) (9CI) (CA INDEX NAME)

HO—Zn—OH

RN 20427-59-2 HCPLUS

CN Copper hydroxide (Cu(OH)2) (8CI, 9CI) (CA INDEX NAME)

HO—Cu—OH

RN 21041-93-0 HCPLUS


CN Cobalt hydroxide (Co(OH)2) (6CI, 8CI, 9CI) (CA INDEX NAME)

HO—Co—OH

RN 21645-51-2 HCPLUS

KATHLEEN FULLER EIC 1700/LAW LIBRARY 308-4290

CN Aluminum hydroxide (Al(OH)3) (9CI) (CA INDEX NAME)



RN 126853-99-4 HCAPLUS

CN Molybdenum hydroxide (9CI) (CA INDEX NAME)

Component	Ratio	Component Registry Number
HO	x	14280-30-9
Mo	x	7439-98-7


IT 1311-10-0, Strontium hydroxide octahydrate

RL: BUU (Biological use, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(hair relaxer compns. contg.

complexing agent activators)

RN 1311-10-0 HCAPLUS

CN Strontium hydroxide (Sr(OH)2), octahydrate (9CI) (CA INDEX NAME)

● 8 H₂O

L30 ANSWER 5 OF 27 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:136991 HCAPLUS

DN 134:198075

TI Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents

IN Patel, Mahesh V.; Chen, Feng-Jing

PA Lipocene, Inc., USA

SO PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-00

ICS A61K009-14; A61K009-16; A61K009-20; A61K009-22; A61K009-28; A61K009-48

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI WO 2001012155	A1	20010222	WO 2000-US18807	20000710
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6309663 B1 20011030 US 1999-375636 19990817

EP 1210063 A1 20020605 EP 2000-947184 20000710

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

US 2001024658 A1 20010927 US 2000-751968 20001229

PRAI US 1999-375636 A 19990817

WO 2000-US18807 W 20000710

AB The present invention relates to triglyceride-free pharmaceutical compns., pharmaceutical systems, and methods for enhanced absorption of hydrophilic therapeutic agents. The compns. and systems include an absorption enhancing carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. A hydrophilic therapeutic agent can be incorporated into the compn., or can be co-administered with the compn. as part of a pharmaceutical system. The invention also provides methods of treatment with hydrophilic therapeutic agents using these compns. and systems. For example, when a compn. contg. Cremophor RH40 0.30, Arlacel 186 0.20, Na taurocholate 0.18, and propylene glycol 0.32 g, resp., was used, the relative absorption of PEG 4000 as a model macromol. drug was enhanced by 99%.

ST hydrophilic drug surfactant absorption enhancement

IT Lysophospholipids

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C18; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Diglycerides

Glycerides, biological studies

Monoglycerides

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C8-10 monoglycerides and diglycerides; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Glycerides, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C8-10, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Glycerides, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C8-18 and C18-unsatd. mono- and di-, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Antibodies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Fc fragment, fusion protein with TNF receptor; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Lung

Mucous membrane

(administration by; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems

(aerosols; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Phenols, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkyl, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Fats and Glyceridic oils, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(almond, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Antiarthritics
(anti-gout agents; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(beads; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Natural products, pharmaceutical
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(belladonna; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(buccal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(capsules; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Gelatins, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(capsules; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Gonadotropins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chorionic; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Analgesics
Anthelmintics
Anti-inflammatory agents
Antiangular agents
Antiarrhythmics
Antiasthmatics
Antibacterial agents
Anticoagulants
Anticonvulsants
Antidepressants
Antidiabetic agents
Antifoaming agents
Antihistamines
Antihypertensives
Antimalarials
Antimigraine agents
Antiparkinsonian agents
Antipsychotics
Antitumor agents
Antitussives
Antiviral agents
Anxiolytics
Blood serum
Buffers
Chelating agents
Compression
Diuretics
Drug delivery systems
Encapsulation
Extrusion, nonbiological
Flavoring materials
Fungicides
Hypnotics and Sedatives
Immunosuppressants
Inotropics
Molding

Muscarinic antagonists
Muscle **relaxants**
Nervous system stimulants
Nutrients
Peptidomimetics
Plasticizers
Preservatives
Protozoacides
Solubilizers
Spheronization
Surfactants
Vaccines
(compns. for enhanced absorption of hydrophilic drugs using combination
of surfactants)
IT Acrylic polymers, biological studies
Alcohols, biological studies
Amides, biological studies
Amino acids, biological studies
Carbohydrates, biological studies
Corticosteroids, biological studies
Cytokines
Diglycerides
Elastins
Enkephalins
Esters, biological studies
Fatty acids, biological studies
Genetic element
Glycerides, biological studies
Glycosides
Interleukin 2
Interleukin 3
Lecithins
Lysophosphatidic acids
Lysophosphatidylcholines
Lysophosphatidylethanolamines
Lysophosphatidylserines
Macromolecular compounds
Nucleic acids
Nucleosides, biological studies
Nucleotides, biological studies
Oligonucleotides
Peptides, biological studies
Phosphatidic acids
Phosphatidylcholines, biological studies
Phosphatidylethanolamines, biological studies
Phosphatidylglycerols
Phosphatidylserines
Phospholipids, biological studies
Platelet-derived growth factors
Polyoxyalkylenes, biological studies
Proteins, general, biological studies
Sex hormones
Shellac
Sterols
Sulfonic acids, biological studies
Tannins
Toxoids
Tumor necrosis factors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for enhanced absorption of hydrophilic drugs using combination

- of surfactants)
- IT Drug delivery systems
 - (controlled-release; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Glycerides, biological studies
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (corn, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Bath preparations
 - (douches; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Drug delivery systems
 - (drops; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Drug delivery systems
 - (elixirs; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Drug delivery systems
 - (emulsions; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Castor oil
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (ethoxylated, Emalex C40; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Corn oil
- Ethers, biological studies
- Palm kernel oil
- Sterols
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Tumor necrosis factor receptors
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (fusion protein with antibody Fc fragment; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Drugs
 - (gastrointestinal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Drug delivery systems
 - (gels; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Drug delivery systems
 - (granules; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Vaccines
 - (hepatitis A; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Vaccines
 - (hepatitis B; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Castor oil
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (hydrogenated, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Vaccines
 - (influenza; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Enzymes, biological studies
 - Thyroid hormones
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Skin preparations (pharmaceutical)
(**keratolytics**; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lipid regulating agents; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(lotions; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Lysophosphatides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lysophosphatidylglycerols; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Vaccines
(measles; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Polymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mucoadhesive; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Vaccines
(mumps; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(nasal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Surfactants
(nonionic; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(ointments, creams; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(ointments; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(oral; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(particles; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(pastes; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(pellets; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Antioxidants
(pharmaceutical; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Infection
(plague, vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyhydric; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

- IT Phosphatidylethanolamines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reaction products, with PEG and PVP; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Drug delivery systems
(rectal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(salts, carnitine; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Drug delivery systems
(solns.; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Sterols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soya, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Drug delivery systems
(sprays; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Monoglycerides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(succinylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Drug delivery systems
(suppositories, vaginal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Drug delivery systems
(suppositories; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Drug delivery systems
(suspensions; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Drug delivery systems
(sustained-release; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Drug delivery systems
(syrups; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Glycosides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thioglycosides, alkyl esters; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Haemophilus influenzae
(type b, conjugated vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Human poliovirus
(vaccine; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Japanese encephalitis virus
Mycobacterium BCG
Neisseria meningitidis
Rabies
Rotavirus
Streptococcus pneumoniae
Typhoid fever
(vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
- IT Drug delivery systems

(vaginal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Human herpesvirus 3
(varicella from, vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Infection
(variola, vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vegetable, ethoxylated, hydrogenated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vegetable, hydrogenated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vegetable; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Fever and Hyperthermia
(yellow, vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.alpha.; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Adrenoceptor antagonists
(.beta.-; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.beta.; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT 9011-29-4, Nikkol GS 6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Nikkol GS 460; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT 9005-25-8, Starch, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(capsules; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT 59277-89-3, Acyclovir
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT 63585-09-1, Foscarnet sodium
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT 50-21-5, Lactic acid, biological studies 50-21-5D, Lactic acid, acyl esters 50-56-6, Oxytocin, biological studies 50-70-4, Sorbitol, biological studies 50-81-7, Ascorbic acid, biological studies 51-15-0, Pralidoxime chloride 51-43-4, Epinephrine 51-55-8, Atropine, biological studies 51-60-5, -Neostigmine methyl sulfate 52-24-4, Thiotepea 53-79-2, Puromycin 56-81-5, Glycerol, biological studies 57-10-3, Palmitic acid, biological studies 57-11-4, Stearic acid, biological studies 57-13-6, Urea, biological studies 57-22-7,

Vincristine 57-55-6, Propylene glycol, biological studies 57-55-6D, Propylene glycol, ethers 57-64-7, Physostigmine salicylate 57-88-5, Cholesterol, biological studies 57-94-3, Tubocurarine chloride 59-05-2, Methotrexate 60-00-4, EDTA, biological studies 60-00-4D, EDTA, conjugates with antipain and chitosan 60-31-1, Acetylcholine chloride 60-33-3, Linoleic acid, biological studies 62-31-7, Dopamine hydrochloride 63-91-2, Phenylalanine, biological studies 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 65-28-1, Phentolamine mesylate 65-85-0, Benzoic acid, biological studies 66-71-7, 1,10-Phenanthroline 67-42-5, EGTA 68-11-1, Thioglycolic acid, biological studies 68-19-9, Vitamin B12 69-65-8, Mannitol 69-72-7, Salicylic acid, biological studies 69-79-4D, Maltose, alkyl esters 69-93-2, Uric acid, biological studies 70-51-9, Deferoxamine 71-27-2, Suxamethonium chloride 74-89-5, Methanamine, biological studies 75-75-2, Methanesulfonic acid 77-19-0, Dicyclomine 77-92-9, Citric acid, biological studies 77-92-9D, Citric acid, glycerides 79-09-4, Propionic acid, biological studies 79-10-7, Acrylic acid, biological studies 79-10-7D, Acrylic acid, polymers 81-24-3, Taurocholic acid 81-25-4, Cholic acid 83-44-3, Deoxycholic acid 87-69-4, Tartaric acid, biological studies 87-69-4D, Tartaric acid, glycerides, biological studies 89-57-6, Mesalamine 89-65-6, Isoascorbic acid 101-26-8, Pyridostigmine bromide 102-71-6, Triethanolamine, biological studies 104-15-4, p-Toluenesulfonic acid, biological studies 107-15-3, Ethylenediamine, biological studies 107-21-1, Ethylene glycol, biological studies 107-92-6, Butyric acid, biological studies 110-15-6, Succinic acid, biological studies 110-16-7, Maleic acid, biological studies 110-17-8, Fumaric acid, biological studies 110-27-0, Isopropyl myristate 111-62-6, Ethyl oleate 112-80-1, Oleic acid, biological studies 114-07-8, Erythromycin 114-80-7, Neostigmine bromide 115-77-5, Pentaerythritol, biological studies 121-44-8, Triethylamine, biological studies 122-20-3, Triisopropanolamine 124-04-9, Adipic acid, biological studies 124-07-2, Caprylic acid, biological studies 128-13-2, Ursodeoxycholic acid 129-06-6, Warfarin sodium 131-49-7, Diatrizoate meglumine 138-36-3, p-Bromobenzenesulfonic acid 140-64-7, Pentamidine isethionate 141-22-0, Ricinoleic acid 141-43-5, Ethanolamine, biological studies 142-62-1, Caproic acid, biological studies 142-91-6, Isopropyl palmitate 143-07-7, Lauric acid, biological studies 143-07-7D, Lauric acid, Macrogol glycerides 144-55-8, Sodium hydrogen carbonate, biological studies 144-62-7, Oxalic acid, biological studies 145-42-6, Sodium taurocholate 147-94-4, Cytarabine 148-24-3, 8-Quinolinol, biological studies 151-21-3, Sodium lauryl sulfate, biological studies 151-41-7, Lauryl sulfate 154-21-2, Lincomycin 155-97-5, Pyridostigmine 299-42-3, Ephedrine 334-48-5, Capric acid 360-65-6, Glycodeoxycholic acid 434-13-9, Lithocholic acid 463-40-1, Linolenic acid 463-79-6, Carbonic acid, biological studies 471-34-1, Calcium carbonate, biological studies 474-25-9, Chenodeoxycholic acid 475-31-0, Glycocholic acid 516-35-8, Taurochenodeoxycholic acid 516-50-7, Taurodeoxycholic acid 526-95-4, Gluconic acid 541-15-1D, Carnitine, fatty acid ester salts 544-35-4, Ethyl linoleate 544-63-8, Myristic acid, biological studies 577-11-7, Sodium docusate 616-91-1, N-Acetylcysteine 640-79-9, Glycochenodeoxycholic acid 665-66-7, Amantadine hydrochloride 737-31-5, Diatrizoate sodium 863-57-0, Sodium glycocholate 865-21-4, Vinblastin 1002-62-6, Sodium caprate 1115-70-4, Metformin hydrochloride 1264-72-8, Colistin sulfate 1309-42-8, Magnesium hydroxide 1310-58-3, Potassium hydroxide, biological studies 1310-73-2, Sodium hydroxide, biological studies 1319-82-0, Aminocaproic acid 1327-43-1, Magnesium aluminum silicate 1330-80-9, Propylene glycol monooleate 1335-30-4, Aluminum silicate 1336-21-6, Ammonium hydroxide 1338-39-2, Span 20 1338-41-6, Sorbitan

monostearate 1338-43-8, Span 80 1397-89-3, Amphotericin B 1403-66-3, Gentamycin 1404-90-6, Vancomycin 1405-20-5, Polymixin B sulfate 1405-37-4, Capreomycin sulfate 1405-87-4, Bacitracin 1492-18-8, Leucovorin calcium 1501-84-4, Rimantadine hydrochloride 1684-40-8, Tacrine hydrochloride 1695-77-8, Spectinomycin 1935-18-8, Palmitoyl carnitine 2016-88-8, Amiloride hydrochloride 2364-67-2, Palmitoyl carnitine 2466-77-5, Lauroyl carnitine 2646-38-0, Sodium chenodeoxycholate 2898-95-5, Sodium ursodeoxycholate 3056-17-5, Stavudine 3485-62-9, Clidinium bromide 3778-73-2, Isofostamide 3858-83-1, P-Aminobenzamidine 4291-63-8, Cladribine 5534-95-2, Pentagastrin 6303-21-5D, Phosphinic acid, dipeptide derivs. 6493-05-6, Pentoxyfylline 7087-68-5, Diisopropylethylamine 7481-89-2, Zalcitabine 7585-39-9D, .beta.-Cyclodextrin, ethers with propanediol 7647-01-0, Hydrochloric acid, biological studies 7648-98-8, Ambenonium 7664-38-2, Phosphoric acid, biological studies 7664-93-9, Sulfuric acid, biological studies 7664-93-9D, Sulfuric acid, alkyl esters, salts, biological studies 7697-37-2, Nitric acid, biological studies 8007-43-0, Sorbitan sesquioleate 8068-28-8, Colistimethate sodium 9001-28-9, Factor IX 9002-01-1, Streptokinase 9002-60-2, Corticotropin, biological studies 9002-92-0, Brij 35 9002-96-4 9003-01-4D, Polyacrylic acid, conjugates with bacitracin 9003-39-8D, Polyvinylpyrrolidone, reaction products with phosphatidylethanolamine 9004-10-8, Insulin, biological studies 9004-17-5, Insulin protamine zinc 9004-32-4D, Carboxymethyl cellulose, conjugates with pepstatin 9004-34-6, Cellulose, biological studies 9004-34-6D, Cellulose, ethers, biological studies 9004-38-0, Cellulose acetate phthalate 9004-57-3, Ethyl cellulose 9004-81-3 9004-95-9, Polyethylene glycol cetyl ether 9004-96-0, Crodet O40 9004-98-2, Polyoxyethylene oleyl ether 9004-99-3 9005-00-9, Polyoxyethylene stearyl ether 9005-02-1, Kessco PEG 300DL 9005-07-6, Kessco PEG 1540DO 9005-08-7 9005-32-7, Alginic acid 9005-63-4D, fatty acid esters 9005-64-5, Tween 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40 9005-67-8, Tween 60 9007-48-1, Plurol Oleique 9007-92-5, Glucagon, biological studies 9011-21-6 9012-76-4, Chitosan 9012-76-4D, Chitosan, conjugates with antipain and EDTA 9015-68-3, Asparaginase 9034-40-6, Gonadotropin releasing hormone 9035-81-8, Trypsin inhibitor 9036-19-5 9039-53-6, Urokinase 9041-08-1, Enoxaparin sodium 9041-93-4, Bleomycin sulfate 9050-31-1, Hydroxypropylmethyl cellulose phthalate 9062-90-2 9063-46-1 9076-44-2, Chymostatin 9078-38-0, Soybean trypsin inhibitor 9087-70-1, Pancreatic trypsin inhibitor 10034-85-2, Hydriodic acid 10035-10-6, Hydrobromic acid, biological studies 10041-19-7D, derivs. 10043-35-3, Boric acid, biological studies 10596-23-3 11000-17-2, Vasopressin 11061-68-0, Human insulin 11140-04-8, Imwitor 988 12584-58-6, Porcine insulin 12629-01-5, Human growth hormone 13265-10-6, Methscopolamine 13284-86-1, Sodium lithocholate 13780-71-7D, Boronic acid, .alpha.-aminoalkyl derivs. 14440-80-3, Stearyl-2-lactylate 14605-22-2, Taurooursodeoxycholic acid 15500-66-0, Pancuronium bromide 15663-27-1, Cisplatin 15686-71-2, Cephalexin 15826-37-6, Cromolyn sodium 16679-58-6, Desmopressin 16960-16-0, Cosyntropin 17438-29-8 18323-44-9, Clindamycin 18883-66-4, Streptozocin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT. 20537-88-6, Amifostine 21215-62-3, Calcitonin human 21645-51-2, Aluminum hydroxide, biological studies 21679-14-1, Fludarabine 22254-24-6, Ipratropium bromide 22882-95-7, Isopropyl linoleate 23031-32-5, Terbutaline sulfate 23214-92-8, Doxorubicin 24356-60-3, Cephapirin sodium 24938-16-7, Eudragit E 25126-32-3, Sincalide 25168-73-4, Sucrose monostearate 25212-88-8, Eudragit L100-55 25322-68-3, Polyethylene glycol 25339-99-5, Sucrose monolaurate

25496-72-4, Monoolein 25597-07-3, Myristoylcarnitine 25637-84-7, Glyceryl dioleate 25637-97-2, Sucrose dipalmitate 26264-14-2D, Propanediol, ethers with .beta.-cyclodextrin 26266-57-9, Sorbitan monopalmitate 26266-58-0, Sorbitan trioleate 26402-22-2, Glyceryl monocaprate 26402-26-6, Glyceryl monocaprylate 26446-38-8, Sucrose monopalmitate 26589-39-9, Eudragit S 26658-19-5, Sorbitan tristearate 26839-75-8, Timolol 27164-46-1, Cefazolin sodium 27195-16-0, Sucrose distearate 27214-38-6, Nikkol MGM 27215-38-9, Imwitor 312 27321-96-6, Solulan C-24 27638-00-2, Glyceryl dilaurate 29122-68-7, Atenolol 30516-87-1, Zidovudine 31694-55-0D, C8-10-esters 33434-24-1, Eudragit RL 33515-09-2, Gonadorelin 33564-30-6, Cefoxitin sodium 34787-01-4, Ticarcillin 36354-80-0, Glyceryl dicaprylate 36791-04-5, Ribavirin 37220-82-9, Peceol 37321-62-3, Lauroglycol 37330-34-0, Bowman-Birk inhibitor 37330-34-0D, Bowman-Birk inhibitor, conjugates with polyacrylic acid 37691-11-5, Antipain 37691-11-5D, Antipain, conjugates with chitosan and EDTA 38916-34-6, Somatostatin 39324-30-6, Pepstatin 39324-30-6D, Pepstatin, conjugates with CM-cellulose 39366-43-3, Magnesium aluminum hydroxide 39438-11-4, Sorbitan monocaprate 41575-94-4, Carboplatin 42057-22-7, Mezlocillin sodium 42540-40-9, Cefamandole nafate 42766-91-6, Nikkol DHC 42907-92-6, Sodium tauro-24,25-dihydrofusidate 47931-85-1, Calcitonin salmon 50700-72-6, Vecuronium bromide 51192-09-7, Tagat 02 51384-51-1, Metoprolol 51822-44-7, Eudragit L 51938-44-4, Sorbitan sesquistearate 52504-24-2, Softigen 767 52581-71-2, Volpo 3 52907-01-4, Cellulose acetate trimellitate 53168-42-6, Myvacet 9-45 53237-50-6 53910-25-1, Pentostatin 53988-07-1, Glyceryl dicaprate 54063-53-5, Propafenone 54392-26-6, Sorbitan monoisostearate 54910-89-3, Fluoxetine 55123-66-5, Leupeptin 56180-94-0, Acarbose 57107-95-6 57171-56-9 57248-88-1, Pamidronate disodium 58561-47-0, Softigen 701 58970-76-6, Bestatin 59227-89-3, 1-Dodecylazacycloheptan-2-one 59703-84-3, Piperacillin sodium 59721-29-8, Camostat mesylate 60177-36-8, Sorbitan monocaprylate 61270-78-8, Cefonicid sodium 61489-71-2, Menotropin 61869-08-7, Paroxetine 62013-04-1, Dirithromycin 62288-83-9, Desmopressin acetate 62893-19-0, Cefoperazone 63527-52-6, Cefotaxime 64228-81-5, Atracurium besylate 64480-66-6, Glycoursodeoxycholic acid 64544-07-6, Cefuroxime axetil 66376-36-1, Alendronate 66419-50-9, Bovine growth hormone 67352-02-7 67655-94-1, Amastatin 68099-86-5, Bepridil hydrochloride 68401-81-0, Ceftizoxime 68795-69-7, Propylene glycol monocaprate 68958-64-5 69049-74-7, Nedocromil sodium 69070-98-0 69227-93-6, Lauryl .beta.-maltopyranoside 69655-05-6, Didanosine 70458-92-3, Pefloxacin 70458-96-7, Norfloxacin 71486-22-1, Vinorelbine 73384-59-5, Ceftriaxone 74011-58-8, Enoxacin 74356-00-6, Cefotetan disodium 74381-53-6, Leuprolide acetate 76420-72-9, Enalaprilat 76470-66-1, Loracarbef 78110-38-0, Aztreonam 79350-37-1, Cefixime 79517-01-4, Octreotide acetate 79665-92-2 79665-93-3 81161-17-3, Esmolol hydrochloride 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin 83869-56-1, Granulocyte-macrophage colony stimulating factor 83905-01-5, Azithromycin 85721-33-1, Ciprofloxacin 87679-37-6, Trandolapril 88669-04-9, Trospectomycin 89703-10-6, FK-448 89987-06-4, Tiludronate 93790-70-6, Cholylsarcosine 93790-72-8, N-Methyltaurocholic acid 93792-59-7, Hydroxypropylmethyl cellulose succinate 94749-08-3, Salmeterol xinafoate 98079-51-7, Lomefloxacin 100986-85-4, Levofloxacin 104227-87-4, Famciclovir 105287-09-0, Aquateric 105462-24-6, Risedronic acid 106392-12-5, Polyoxyethylene-polyoxypropylene block copolymer 106819-53-8, Doxacurium chloride 106861-44-3, Mivacurium chloride 107648-80-6, Cefepime hydrochloride 110871-86-8, Sparfloxacin 113189-02-9, Antihemophilic factor 113852-37-2, Cidofovir 116094-23-6, Insulin aspart 119914-60-2, Grepafloxacin 121368-58-9, Olpadronate 121548-04-7, Gelucire 44/14

121548-05-8, Gelucire 50/13 124832-26-4, Valaciclovir 126467-48-9, Porcine somatotropin 127759-89-1, Lobucavir 133107-64-9, Insulin lispro 134678-17-4, Lamivudine 137862-53-4, Valsartan 138636-14-3, Eudragit NE 139110-80-8, Zanamivir 139639-23-9, Tissue type plasminogen activator 141644-88-4, Hydrotalcite 142368-40-9, Imwitor 375 143003-46-7, Alglucerase 143011-72-7, Granulocyte colony stimulating factor 146961-76-4, Alatrofloxacin 147059-72-1, Trovafloxacin 148046-81-5, Gelucire 33/01 148553-50-8, Pregabalin 150372-93-3, Glycerox L 151126-32-8, Pramlintide 154361-50-9, Capecitabine 156259-68-6, Capmul MCM 157810-81-6, Indinavir sulfate 160337-95-1, Insulin glargine 169148-63-4, Insulin detemir 173146-27-5, Denileukin diftitox 191588-94-0, TNK-tPA 211365-88-7, Nikkol BPS 30

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT 9001-92-7, Proteinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT 9003-98-9, Dornase 11096-26-7, Epoetin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.alpha.; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Cho; US 5858398 A 1999 HCAPLUS


IT 1309-42-8, Magnesium hydroxide 21645-51-2, Aluminum hydroxide, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

RN 1309-42-8 HCAPLUS

CN Magnesium hydroxide (Mg(OH)2) (9CI) (CA INDEX NAME)



RN 21645-51-2 HCAPLUS
CN Aluminum hydroxide (Al(OH)3) (9CI) (CA INDEX NAME)



L30 ANSWER 6 OF 27 HCAPLUS COPYRIGHT 2002 ACS
AN 2001:31287 HCAPLUS
DN 134:105670
TI Pharmaceutical and cosmetic **compositions** containing oligosaccharide aldonic acids and their topical use
IN Yu, Ruey J.; Van Scott, Eugene J.
PA USA
SO PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K007-00

CC 62-6 (Essential Oils and Cosmetics)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001001932	A2	20010111	WO 2000-US16301	20000628
	WO 2001001932	A3	20010517		
				W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
	US 6335023	B1	20020101	US 2000-487228	20000119
	US 2002028227	A1	20020307	US 2001-987023	20011113
PRAI	US 1999-141264P	P	19990630		
	US 2000-487228	A	20000119		
OS	MARPAT	134:105670			
AB	Compns. comprising oligosaccharide aldonic acids are useful for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatol. disorders, including those assocd. with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors; general care, as well as treatment and prevention of diseases and conditions, of the oral, and vaginal mucosa; for general oral care, as well as treatment and prevention of oral and gum diseases; and for wound healing of the skin. Compns. comprising oligosaccharide aldonic acids may further comprise a cosmetic, pharmaceutical or other topical agent to enhance or create synergistic effects. A cream was prep'd. by mixing 50 g of 50% maltobionic acid with 50 g oil-in-water base, pH = 1.7. Efficacy of topical maltobionic acid in treatment of dry skin is reported.				
ST	topical pharmaceutical cosmetic oligosaccharide aldonic acid				
IT	Amino acids, biological studies RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (N-acetyl derivs.; pharmaceutical and cosmetic compns. contg. oligosaccharide aldonic acids and their topical use)				
IT	Carboxylic acids, biological studies RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Ph-alpha acyloxy derivs.; pharmaceutical and cosmetic compns. contg. oligosaccharide aldonic acids and their topical use)				
IT	Skin, disease (aging; pharmaceutical and cosmetic compns. contg. oligosaccharide aldonic acids and their topical use)				
IT	Carbohydrates, biological studies RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (aldonic acids; pharmaceutical and cosmetic compns. contg. oligosaccharide aldonic acids and their topical use)				
IT	Amines, biological studies RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alkoxylated; pharmaceutical and cosmetic compns. contg.				

oligosaccharide aldonic acids and their topical use)

IT Alcohols, biological studies

Amides, biological studies

Cyclitols

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino; pharmaceutical and cosmetic **compns.** contg.

oligosaccharide aldonic acids and their topical use)

IT Cosmetics

(antiaging; pharmaceutical and cosmetic **compns.** contg.

oligosaccharide aldonic acids and their topical use)

IT Hair preparations

(conditioners; pharmaceutical and cosmetic **compns.** contg.

oligosaccharide aldonic acids and their topical use)

IT Skin, disease

(dry; pharmaceutical and cosmetic **compns.** contg.

oligosaccharide aldonic acids and their topical use)

IT Amino acids, biological studies

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(esters; pharmaceutical and cosmetic **compns.** contg.

oligosaccharide aldonic acids and their topical use)

IT Amines, biological studies

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(fatty; pharmaceutical and cosmetic **compns.** contg.

oligosaccharide aldonic acids and their topical use)

IT Keratosis

(follicularis; pharmaceutical and cosmetic **compns.** contg.

oligosaccharide aldonic acids and their topical use)

IT Drug delivery systems

(gels; pharmaceutical and cosmetic **compns.** contg.

oligosaccharide aldonic acids and their topical use)

IT Carbohydrates, biological studies

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(glycosylamines; pharmaceutical and cosmetic **compns.** contg.

oligosaccharide aldonic acids and their topical use)

IT Carboxylic acids, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(hydroxy; pharmaceutical and cosmetic **compns.** contg.

oligosaccharide aldonic acids and their topical use)

IT Keratosis

(hyperkeratosis, plantar; pharmaceutical and cosmetic **compns.** contg.

oligosaccharide aldonic acids and their topical use)

IT Skin, disease

(ichthyosis; pharmaceutical and cosmetic **compns.** contg.

oligosaccharide aldonic acids and their topical use)

IT Dermatitis

Motion sickness

Seborrhea

Yeast

(inhibitors; pharmaceutical and cosmetic **compns.** contg.

oligosaccharide aldonic acids and their topical use)

IT Keratins

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(keratoses; pharmaceutical and cosmetic compns.
contg. oligosaccharide aldonic acids and their topical use)

IT Skin, disease
(lichen planus; pharmaceutical and cosmetic compns. contg.
oligosaccharide aldonic acids and their topical use)

IT Skin, disease
(melasma; pharmaceutical and cosmetic compns. contg.
oligosaccharide aldonic acids and their topical use)

IT Drug delivery systems
(ointments, creams; pharmaceutical and cosmetic compns.
contg. oligosaccharide aldonic acids and their topical use)

IT Carboxylic acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic
use); BIOL (Biological study); USES (Uses)
(oxo; pharmaceutical and cosmetic compns. contg.
oligosaccharide aldonic acids and their topical use)

IT Acne

Amphoteric materials

Analgesics

Anesthetics

Anti-inflammatory agents

Antibacterial agents

Antiemetics

Antihistamines

Antioxidants

Antiperspirants

Antiviral agents

Burn

Cardiovascular agents

Cosmetics

Dandruff

Eczema

Fungicides

Hair

Human herpesvirus

Nail (anatomical)

Pruritus

Psoriasis

Shale oils

Skin.

Sunscreens

Suntanning agents

Wart

Wound healing
(pharmaceutical and cosmetic compns. contg. oligosaccharide
aldonic acids and their topical use)

IT Coal tar

Corticosteroids, biological studies

Elastins

Esters, biological studies

Glycosaminoglycans, biological studies

Hormones, animal, biological studies

Lactones

Oligosaccharides, biological studies

Proteoglycans, biological studies

Retinoids

Salts, biological studies

Vitamins

Wood tar

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical and cosmetic compns. contg. oligosaccharide aldonic acids and their topical use)

IT Alkali metal hydroxides
Amine oxides
Amines, biological studies
Imines
Peptides, biological studies
Polyamines
Proteins, general, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical and cosmetic compns. contg. oligosaccharide aldonic acids and their topical use)

IT Resins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(podophyllum; pharmaceutical and cosmetic compns. contg. oligosaccharide aldonic acids and their topical use)

IT Cosmetics
(skin-lightening; pharmaceutical and cosmetic compns. contg. oligosaccharide aldonic acids and their topical use)

IT Drug delivery systems
(topical; pharmaceutical and cosmetic compns. contg. oligosaccharide aldonic acids and their topical use)

IT Cosmetics
(wrinkle-preventing; pharmaceutical and cosmetic compns. contg. oligosaccharide aldonic acids and their topical use)

IT 50-02-2, Dexamethasone 50-03-3, Hydrocortisone 21-acetate 50-21-5, Lactic acid, biological studies 50-23-7, Hydrocortisone 50-28-2, Estradiol, biological studies 50-48-6, Amitriptyline 50-78-2, Acetylsalicylic acid 50-81-7, Ascorbic acid, biological studies 51-03-6, Piperonyl butoxide 51-21-8, 5-Fluorouracil 51-55-8, Atropine, biological studies 53-43-0, Dehydroepiandrosterone 53-86-1, Indomethacin 55-56-1, Chlorhexidine 57-13-6, Urea, biological studies 57-63-6, Ethinyl estradiol 58-73-1, Diphenhydramine 58-95-7, Vitamin E acetate 59-33-6, Pyrilamine 59-42-7, Phenylephrine 59-46-1, Procaine 60-54-8, Tetracycline 64-65-3, Bemegride 65-45-2, Salicylamide 67-73-2, Fluocinolone acetonide 67-78-7, Triamcinolone diacetate 68-26-8, Retinol 68-35-9, Sulfadiazine 68-41-7, Cycloserine 68-88-2, Hydroxyzine 68-95-1, N-Acetylproline 69-72-7, Salicylic acid, biological studies 76-22-2, Camphor 76-25-5, Triamcinolone acetonide 79-14-1, Glycolic acid, biological studies 79-81-2, Retinyl palmitate 84-22-0, Tetrahydrozoline 86-21-5, Pheniramine 86-22-6, Brompheniramine 89-83-8, Thymol 90-45-9, Aminacrine 90-64-2, Mandelic acid 90-82-4, Pseudoephedrine 93-14-1, Guaifenesin 93-60-7, Methyl nicotinate 94-24-6, Tetracaine 94-36-0, Benzoyl peroxide, biological studies 96-88-8, Mepivacaine 103-16-2, Monobenzone 108-46-3, Resorcinol, biological studies 108-95-2, Phenol, biological studies 112-38-9, Undecylenic acid 113-92-8 114-07-8, Erythromycin 116-31-4, Retinal 118-56-9, Homosalate 118-60-5, Octyl salicylate 119-36-8, Methyl salicylate 119-61-9, Benzophenone, biological studies 121-29-9, Pyrethrin 123-31-9, Hydroquinone, biological studies 123-31-9D, Hydroquinone, monoether derivs. 123-99-9, Azelaic acid, biological studies 124-43-6, Carbamide peroxide 126-07-8, Griseofulvin 127-47-9, Retinyl acetate 130-26-7, Clioquinol 131-57-7, Oxybenzone 136-77-6, Hexylresorcinol 137-58-6, Lidocaine 137-66-6, Ascorbyl

palmitate 139-12-8, Aluminum acetate 140-65-8, Pramoxine 302-79-4,
 Retinoic acid 356-12-7, Fluocinonide 382-67-2, Desoximetasone
 404-86-4, Capsaicin 443-48-1, Metronidazole 483-63-6, Crotamiton
 486-12-4, Triprolidine 499-14-9, Chondrosine 499-15-0, Hyalobiuronic
 acid 501-30-4, Kojic acid 518-28-5, Podofilox 525-66-6, Propranolol
 534-41-8, Celllobionic acid 534-42-9, Maltobionic acid 534-74-7,
 Isomaltobionic acid 547-64-8, Methyl lactate 562-10-7, Doxylamine
 569-65-3, Meclizine 584-63-4 586-60-7, Dyclonine 721-50-6,
 Prilocaine 768-94-5, Amantadine 777-11-7, Haloprogin 1143-38-0,
 Anthralin 1198-84-1, 4-Hydroxymandelic acid 1319-82-0, Aminocaproic
 acid 1321-11-5, Aminobenzoic acid 1321-23-9, Chloroxylenol
 1327-41-9, Aluminum chlorhydroxide 1400-61-9, Nystatin 1404-04-2,
 Neomycin 1405-87-4, Bacitracin 1406-18-4, Vitamin e 1490-04-6,
 Menthol 1491-59-4, Oxymetazoline 1668-19-5, Doxepin 2013-58-3,
 Meclocycline 2152-44-5, Betamethasone valerate 2398-96-1, Tolnaftate
 3380-34-5, Triclosan 3808-00-2 4759-48-2, 13-Cis-Retinoic acid
 5438-68-6 5466-77-3, Octyl 4-methoxycinnamate 5534-09-8,
 Beclomethasone dipropionate 5551-59-7, Celllobiouronic acid 5593-20-4,
 Betamethasone dipropionate 5611-51-8, Triamcinolone hexacetonide
 5965-65-1, Lactobionolactone 7446-70-0, Aluminum chloride, biological
 studies 7512-17-6, N-Acetylglucosamine 7704-34-9, Sulfur, biological
 studies 7722-84-1, Hydrogen peroxide, biological studies 8029-68-3,
 Ichthammol 9012-76-4, Chitosan 10118-90-8, Minocycline 11103-57-4,
 Vitamin a 12650-69-0, Mupirocin 13431-32-8 13463-41-7, Zinc
 pyrithione 13609-67-1, Hydrocortisone 17-butyrate 14838-15-4,
 Phenylpropanolamine 15686-51-8, Clemastine 15687-27-1, Ibuprofen
 16110-51-3, Cromolyn 18323-44-9, Clindamycin 18559-94-9, Albuterol
 21245-02-3 21645-51-2, Aluminum hydroxide, biological studies
 21675-38-7, Melibionic acid 22071-15-4, Ketoprofen 22204-53-1,
 Naproxen 22916-47-8, Miconazole 23593-75-1, Clotrimazole 25122-46-7,
 Clobetasol propionate 25655-41-8, Povidone iodine 27220-47-9,
 Econazole 28088-64-4, Aminosalicylic acid 28631-45-0D, lactone from
 29342-05-0, Ciclopirox 30233-46-6 34150-97-5D, lactone from
 38304-91-5, Minoxidil 38396-39-3, Bupivacaine 42776-28-3,
 Maltobionolactone 50612-42-5 52645-53-1, Permethrin 52762-22-8,
 Cellbionolactone 56093-45-9, Selenium sulfide 56933-14-3
 57524-89-7, Hydrocortisone 17-valerate 59277-89-3, Acyclovir
 61318-90-9, Sulconazole 64211-45-6, Oxiconazole 64872-76-0,
 Butoconazole 65277-42-1, Ketoconazole 65472-88-0, Naftifine
 65899-73-2, Tioconazole 67915-31-5, Terconazole 77893-25-5
 77893-26-6 91161-71-6, Terbinafine 99011-02-6, Imiquimod
 106685-40-9, Adapalene 110558-39-9 110574-00-0 112965-21-6,
 Calcipotriene 118292-40-3, Tazarotene 184241-84-7 207738-18-9
 318471-21-5 318471-22-6 318471-23-7 318471-24-8 318471-25-9
 318471-26-0 318471-27-1 318471-28-2 318471-29-3 318471-30-6
 318471-31-7 318471-32-8 318471-33-9 318471-34-0 318471-35-1
 318471-36-2 318471-37-3 318471-38-4 318471-57-7
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic
 use); BIOL (Biological study); USES (Uses)
 (pharmaceutical and cosmetic compns. contg. oligosaccharide
 aldonic acids and their topical use)

IT 52-90-4, L-Cysteine, biological studies 56-40-6, Glycine, biological
 studies 56-85-9, L-Glutamine, biological studies 56-87-1, Lysine,
 biological studies 57-00-1, Creatine 60-27-5, Creatinine 71-00-1,
 L-Histidine, biological studies 73-22-3, Tryptophan., biological studies
 74-79-3, Arginine, biological studies 75-31-0, Isopropylamine,
 biological studies 77-86-1, Tromethamine 78-96-6, Isopropanolamine
 96-20-8 102-71-6, Triethanolamine, biological studies 108-18-9,
 Diisopropylamine 109-83-1, Methyllethanamine 110-91-8, Morpholine,

biological studies 110-97-4, Diisopropanolamine 111-42-2,
 Diethanolamine, biological studies 113-00-8D, Guanidine, derivs.
 115-69-5 115-70-8 122-20-3, Triisopropanolamine 124-68-5 127-09-3,
 Sodium acetate 144-55-8, Sodium bicarbonate, biological studies
 147-85-3, L-Proline, biological studies 372-75-8, Citrulline 459-73-4,
 Glycine ethyl ester 488-43-7, Glucamine 497-19-8, Sodium carbonate,
 biological studies 506-87-6, Ammonium carbonate 543-38-4, Canavanine
 598-41-4, Glycinamide 687-64-9, Lysine methyl ester 1066-33-7,
 Ammonium bicarbonate 1310-73-2, Sodium hydroxide, biological studies
 1336-21-6, Ammonium hydroxide 2812-47-7, Prolinamide 6169-96-6,
 Lysinamide 6284-40-8, N-Methylglucamine 7429-90-5D, Aluminum, salts,
 biological studies 7439-93-2D, Lithium., salts 7439-95-4D, Magnesium,
 salts, biological studies 7440-24-6D, Strontium, salts, biological
 studies 7440-66-6D, Zinc, salts, biological studies 7440-70-2D,
 Calcium, salts, biological studies 7632-05-5, Sodium phosphate
 10124-31-9, Ammonium phosphate 16709-23-2, Argininamide 16889-14-8,
 Stearamidoethyl diethylamine 20182-63-2, Stearamidopropyl dimethylamine
 25497-48-7, Dipropylenetriamine 28299-33-4D, Imidazoline, derivs.
 28696-31-3, Arginine ethyl ester 60169-67-7, Proline ethyl ester
 63224-20-4 104240-72-4

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(pharmaceutical and cosmetic compns. contg. oligosaccharide
 aldonic acids and their topical use)


IT 21645-51-2, Aluminum hydroxide, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic
 use); BIOL (Biological study); USES (Uses)

(pharmaceutical and cosmetic compns. contg. oligosaccharide
 aldonic acids and their topical use)

RN 21645-51-2 HCPLUS

CN Aluminum hydroxide (Al(OH)3) (9CI) (CA INDEX NAME)



L30 ANSWER 7 OF 27 HCPLUS COPYRIGHT 2002 ACS

AN 2001:12218 HCPLUS

DN 134:76147

TI Topical anti-microbial compositions containing pyrithione and
 metal ions

IN Gavin, David Francis; Marchetta, Anthony Raymond; Nelson, John Daniel;
 Polson, George; Schwartz, James Robert; Turley, Patricia Aileen

PA The Procter & Gamble Company, USA; Arch Chemicals, Inc.

SO PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K007-06

ICS A61K007-48; A61K033-24

CC 62-4 (Essential Oils and Cosmetics)

Section cross-reference(s): 63

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001000151	A1	20010104	WO 2000-US17273	20000623

W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
 CU, CZ, CZ, DE, DE, DK, DK, DM, EE, EE, ES, FI, FI, GB, GD, GE,
 GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
 LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
 UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1189581 A1 20020327 EP 2000-944806 20000623

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO

BR 2000011852 A 20020430 BR 2000-11852 20000623

PRAI US 1999-141195P P 19990625
 US 2000-599624 A 20000622
 WO 2000-US17273 W 20000623

AB Disclosed are topical **compns.** for the treatment of microbial infections on the skin or scalp which include a polyvalent metal salt of pyrithione and include a metal ion source. Also disclosed are methods for treating microbial infections of the skin or scalp using such **compns.** The efficacy of Zn pyrithione in combination with metal ions such as Cu, Zn, Ni, and Hg against Malassezia furfur microorganism.

ST topical antimicrobial pyrithione metal ion

IT Antibacterial agents

Antimicrobial agents

Cosmetics

Hair preparations

 Shampoos

 Surfactants

 (topical anti-microbial **compns.** contg. pyrithione and metal ions)

IT Coal tar

RL: BUU (Biological use, unclassified); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

 (topical anti-microbial **compns.** contg. pyrithione and metal ions)

IT Drug delivery systems

 (topical; topical anti-microbial **compns.** contg. pyrithione and metal ions)

IT Tannins

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

 (zinc salts; topical anti-microbial **compns.** contg. pyrithione and metal ions)

IT 13463-41-7, Zinc pyrithione

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

 (topical anti-microbial **compns.** contg. pyrithione and metal ions)

IT 14807-96-6, Talc, biological studies 65277-42-1, Ketoconazole

84625-61-6, Itraconazole

RL: BUU (Biological use, unclassified); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

 (topical anti-microbial **compns.** contg. pyrithione and metal ions)

IT 546-46-3, Zinc citrate 547-68-2, Zinc oxalate 551-64-4, biological studies 556-38-7, Zinc valerate 557-05-1, Zinc stearate 557-07-3, Zinc oleate 557-08-4, Zinc undecylenate 557-28-8, Zinc propionate 557-34-6, Zinc acetate 1314-13-2, Zinc oxide, biological studies

1314-98-3, Zinc sulfide, biological studies 1317-39-1, Cuprous oxide, biological studies 1332-40-7, Copper oxychloride 1344-67-8, Copper chloride 3486-35-9, Zinc carbonate 4468-02-4, Zinc gluconate 7439-97-6D, Mercury, salts, biological studies 7440-02-0D, Nickel, salts, biological studies 7440-22-4D, Silver, salts, biological studies 7440-43-9D, Cadmium, salts, biological studies 7440-50-8D, Copper, salts, biological studies 7440-66-6D, Zinc, salts, biological studies 7440-69-9D, Bismuth, salts, biological studies 7447-39-4, Cupric chloride, biological studies 7487-88-9, Magnesium sulfate, biological studies 7492-68-4, Copper carbonate 7646-85-7, Zinc chloride, biological studies 7733-02-0, Zinc sulfate 7758-89-6, Copper chloride 7758-98-7, Copper sulfate, biological studies 7779-90-0, Zinc phosphate 7783-49-5, Zinc fluoride 7785-87-7, Manganese sulfate 7787-60-2, Bismuth chloride 8012-69-9, Copper oxychloride sulfate 10139-47-6, Zinc iodide 10294-26-5, Silver sulfate 11126-29-7, Zinc silicate 13426-91-0, Copper ethylenediamine **complex** 13597-54-1, Zinc selenate 16039-53-5, Zinc lactate 16283-36-6, Zinc salicylate 20427-58-1, Zinc hydroxide 20427-59-2, Cupric hydroxide 26656-82-6, Copper thiocyanate 31089-39-1, Copper triethanolamine 41229-70-3, Cuprous ammonium carbonate 56093-45-9, Selenium sulfide 73342-99-1

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical anti-microbial **compns.** contg. pyrithione and metal ions)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Beecham Group; EP 0077630 A 1983 HCPLUS
(2) Kooistra, J; US 3852441 A 1974 HCPLUS
(3) Wiese, R; US 5227156 A 1993 HCPLUS

IT 20427-58-1, Zinc hydroxide 20427-59-2, Cupric hydroxide
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical anti-microbial **compns.** contg. pyrithione and metal ions)

RN 20427-58-1 HCPLUS

CN Zinc hydroxide (Zn(OH)2) (9CI) (CA INDEX NAME)

HO—Zn—OH

RN 20427-59-2 HCPLUS
CN Copper hydroxide (Cu(OH)2) (8CI, 9CI) (CA INDEX NAME)

HO—Cu—OH

L30 ANSWER 8 OF 27 HCPLUS COPYRIGHT 2002 ACS
AN 2000:383884 HCPLUS
DN 133:22149
TI Hair dye **compositions** containing oxidoreductase and mediators
IN Sorensen, Niels Henrik; McDevitt, Jason Patrick
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DT Patent

LA English
 IC ICM A61K007-13
 ICS A61K007-09

CC 62-3 (Essential Oils and Cosmetics)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000032158	A1	20000608	WO 1999-DK674	19991201
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1137391	A1	20011004	EP 1999-957262	19991201
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRAI US 1998-203075 A 19981201

WO 1999-DK674 W 19991201

AB A method for treating hair, combining permanent dyeing and straightening of hair, without significantly damaging the hair is disclosed. The hair is treated by chem. reducing covalent disulfide linkages in the hair, and contacting said hair with at least 1 oxidoreductase, at least 1 mediator, and at least 1 chem. oxidizing agent in an amt. equiv. to 0.001-1% hydrogen peroxide of the dyeing formulation. The efficiency of dyeing of blonde hair was improved when dyeing was performed on chem. straightened hair relative to-untreated hair.

ST hair dye oxidoreductase mediator; oxidase hair dye mediator

IT Phenols, biological studies

Phenols, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(amino; hair dye compns. contg. oxidoreductase and mediators)

IT Amines, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(diamines; hair dye compns. contg. oxidoreductase and mediators)

IT Hair preparations

(dyes, oxidative; hair dye compns. contg. oxidoreductase and mediators)

IT Hair preparations

(dyes; hair dye compns. contg. oxidoreductase and mediators)

IT Hair

(hair dye compns. contg. oxidoreductase and mediators)

IT Phenols, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(hair dye compns. contg. oxidoreductase and mediators)

IT Amines, biological studies

Amines, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(phenolic; hair dye compns. contg. oxidoreductase and mediators)

IT 60-18-4, L-Tyrosine, biological studies 81-11-8, 4,4'-Diaminostilbene-2,2'-disulfonic acid 84-08-2 84-97-9, 10-[3-(4-Methyl-1-piperazinyl)propyl]phenothiazine 92-87-5, Benzidine 92-88-6, [1,1'-Biphenyl]-4,4'-diol 99-96-7, 4-Hydroxybenzoic acid, biological studies 106-50-3, p-Phenylenediamine, biological studies 119-79-9, 5-Amino-2-naphthalenesulfonic acid 119-90-4, 3,3'-Dimethoxybenzidine 119-93-7, 3,3'-Dimethylbenzidine 123-30-8, p-Aminophenol 130-17-6 134-96-3, Syringaldehyde 256-96-2, Iminostilbene 327-97-9, Chlorogenic acid 331-39-5, Caffeic acid 362-03-8, 10-Phenothiazinepropionic acid 362-04-9, Methyl 10-phenothiazinepropionate 494-44-0, 7-Amino-2-naphthalenesulfonic acid 525-64-4, 2,7-Diaminofluorene 530-57-4, Syringic acid 530-59-6, Sinapic acid 537-65-5, 4,4'-Diaminodiphenylamine 591-27-5, 3-Aminophenol 603-34-9, Triphenylamine 611-99-4, 4,4'-Dihydroxybenzophenone 884-35-5, Methylsyringate 1135-24-6, Ferulic acid 1207-72-3, 10-Methylphenothiazine 1637-16-7, 10-Ethylphenothiazine 1696-60-2, Vanillin azine 1749-04-8, N-[4-(Dimethylamino)benzylidene]-p-anisidine 2243-62-1, 1,5-Diaminonaphthalene 2478-38-8, Acetosyringone 2814-61-1, 2,2'-Azinobis(3-ethylbenzothiazoline6-sulfonate 3943-80-4, Ethyl syringate 5060-82-2, 7-Methoxy-2-naphthol 6972-56-1, 1H-Naphth[1,2-d]imidazol-7-ol 7046-84-6, 10-(2-Hydroxyethyl)phenothiazine 7152-42-3, 10-Phenylphenothiazine 7570-37-8, 4-Amino-4'-methoxystilbene 7722-84-1, Hydrogen peroxide, biological studies 9003-99-0, Peroxidase 9035-73-8, Oxidase 11138-47-9, Sodium perborate 13924-28-2, N-Benzylidene-4-biphenylamine 15375-48-1, 10-Propylphenothiazine 16712-64-4, 6-Hydroxy-2-naphthoic acid 17427-04-2, 10-Isopropylphenothiazine 20962-92-9, 10-Allylphenothiazine 21429-17-4 21977-42-4, 10-Phenoxyazinepropionic acid 25324-52-1, 2-Acetyl-10-methylphenothiazine 25782-99-4, 10-Methylphenoxyazine 27151-57-1, 4,4'-Dimethoxy-N-methyldiphenylamine 54827-17-7, 3,3',5,5'-Tetramethylbenzidine 58574-03-1, 4'-Hydroxy-4-biphenylcarboxylic acid 60411-11-2, 10-Ethyl-4-phenothiazinecarboxylic acid 63397-92-2, 10-(3-Hydroxypropyl)phenothiazine 69113-98-0 72684-97-0, Propyl syringate 80498-15-3, Laccase 90510-22-8, Hexyl syringate 92199-64-9, 10-(2-Hydroxyethyl)phenoxyazine 136832-74-1 177959-98-7, Butyl syringate 177959-99-8, Octyl syringate

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(hair dye compns. contg. oxidoreductase and mediators)

IT 113-00-8D, Guanidine, quaternized, hydroxides 1305-62-0, Calcium hydroxide (Ca(OH)2), processes 1310-73-2, Sodium hydroxide, processes

RL: PEP (Physical, engineering or chemical process); PROC (Process)

(hair dye compns. contg. oxidoreductase and mediators)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Eugene, Z; US 3957424 A 1976 HCPLUS
- (2) Goldwell Aktiengesellschaft; EP 0548620 A1 1993 HCPLUS
- (3) L'Oreal; FR 2694018 A1 1994 HCPLUS
- (4) Novo Nordisk AS; WO 9610079 A1 1996 HCPLUS
- (5) Novo Nordisk AS; WO 9815257 A1 1998 HCPLUS
- (6) Novo Nordisk AS; WO 9958013 A1 1999 HCPLUS
- (7) Yoshio; US 4961925 A 1990 HCPLUS

IT 1305-62-0, Calcium hydroxide (Ca(OH)2), processes
 RL: PEP (Physical, engineering or chemical process); PROC (Process)
 (hair dye compns. contg. oxidoreductase and
 mediators)
 RN 1305-62-0 HCPLUS
 CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)

HO—Ca—OH

L30 ANSWER 9 OF 27 HCPLUS COPYRIGHT 2002 ACS
 AN 1999:636065 HCPLUS
 DN 131:248035
 TI Alkaline hair-conditioning compositions containing
 cationic guar
 IN Varco, Joseph J.
 PA Bristol-Myers Squibb Co., USA
 SO Eur. Pat. Appl., 10 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 IC ICM A61K007-09
 CC 62-3 (Essential Oils and Cosmetics)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	EP 943315	A2	19990922	EP 1999-200643	19990304	
	EP 943315	A3	20010829			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
	US 6010690	A	20000104	US 1998-35392-	19980305	
	BR 9900880	A	20000328	BR 1999-880	19990304	
PRAI	US 1998-35392	A	19980305			
OS	MARPAT 131:248035					
AB	The invention provides compns. for relaxing and conditioning keratinous fibers, particularly human hair. The compns. of the present invention have a high pH, i.e., a pH greater than 10, preferably, in the range of about 11 to about 14, more preferably about 12 to about 13.5; and include as a conditioning additive a cationic guar. Surprisingly, the cationic guar maintains stability, viscosity and activity over time in the highly alk. pH of the inventive hair relaxer and conditioning compns. of the present invention. The relaxer compns. of the present invention afford beneficial effects to the user, such as softness and ease of wet combing, and cause less damage to hair following application and use. In addn., the conditioning relaxer compns. of the present invention remain on the hair and provide lasting conditioning and relaxing effects after one or more shampoos.					
ST	hair conditioner cationic guar alk hydroxide					
IT	Alkaline earth hydroxides Amines, biological studies Quaternary ammonium compounds, biological studies RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (alk. hair-conditioning compns. contg. cationic guar)					
IT	Hair preparations					

(conditioners; alk. hair-conditioning compns.
contg. cationic guar)

IT 64-67-5, Ethyl sulfate 1305-62-0, Calcium hydroxide, biological studies 1310-58-3, Potassium hydroxide, biological studies 1310-65-2, Lithium hydroxide 1310-73-2, Sodium hydroxide, biological studies 17194-00-2, Barium hydroxide 18480-07-4, Strontium hydroxide 65497-29-2, Guar hydroxypropyltrimonium chloride 81646-13-1 81859-24-7, Polyquaternium 10
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(alk. hair-conditioning compns. contg. cationic guar)

IT 1305-62-0, Calcium hydroxide, biological studies
17194-00-2, Barium hydroxide 18480-07-4, Strontium hydroxide
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(alk. hair-conditioning compns. contg. cationic guar)

RN 1305-62-0 HCAPLUS
CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)

HO—Ca—OH

RN 17194-00-2 HCAPLUS
CN Barium hydroxide (Ba(OH)2) (9CI) (CA INDEX NAME)

HO—Ba—OH

RN 18480-07-4 HCAPLUS
CN Strontium hydroxide (Sr(OH)2) (9CI) (CA INDEX NAME)

HO—Sr—OH

L30 ANSWER 10 OF 27 HCAPLUS COPYRIGHT 2002 ACS
AN 1998:681931 HCAPLUS
DN 129:306297
TI Shampoo compositions for decreasing combing damage
IN Syed, Ali N.; Ahmad, Kaleem
PA Avlon Industries, Inc., USA
SO U.S., 18 pp., Cont.-in-part of U.S. Ser. No. 267,829, abandoned.
CODEN: USXXAM

DT Patent
LA English
IC ICM A61K007-06
 ICS A61K007-09

NCL 424070400

CC 62-3 (Essential Oils and Cosmetics)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5824295	A	19981020	US 1996-627345	19960404
	ZA 9509299	A	19970505	ZA 1995-9299	19951103

PRAI US 1994-267829 B2 19940629

AB A compn. for treating hair includes at least 1 of the following: a cationic polymer made from the reaction of secondary amines with epihalohydrin and further crosslinked with the addn. of a small amt. of ethylene diamine; poly(dimethylaminoethyl methacrylate) and 1 of a precomponent of an active hair relaxing ingredient, guanidine hydroxide or a shampoo base; Polyquaternium 10 and at least 1 of an active hair relaxing ingredient and an active hair relaxing ingredient; and Polyquaternium 32 and mineral oil. A method of using at least 1 of a cationic polymer, poly(dimethylaminoethyl methacrylate), Polyquaternium 10 or Polyquaternium 32 includes the steps of applying 1 of the above to hair that is in risk of damage from a cosmetic procedure and exposing the hair to a cosmetic procedure. Thus, a shampoo contained water 79.3, methylparaben 0.2, propylparaben 0.1, imidazolidinylurea 0.35, disodium-EDTA 0.2, citric acid 1.6, Betz-1195 2, cocoamphocarboxypropionate 8, ammonium lauryl sulfate 0.75, cocoamide diethanolamine 4, Polysorbate-20 3 and fragrance 0.5% by wt.

ST shampoo hair combing damage cationic polymer

IT Onium compounds

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(1-[2-(carboxymethoxy)ethyl]-1-(carboxymethyl)-4,5-dihydro-2-norcoco alkyl imidazolium, inner salts, disodium salts; shampoo compns. for decreasing hair combing damage)

IT Polyelectrolytes

(cationic; shampoo compns. for decreasing hair combing damage)

IT Amides, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(coco, N,N-bis(hydroxyethyl); shampoo compns. for decreasing hair combing damage)

IT Hair preparations

(conditioners; shampoo compns. for decreasing hair combing damage)

IT Alcohols, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(polyhydric; shampoo compns. for decreasing hair combing damage)

IT Hair

Shampoos

(shampoo compns. for decreasing hair combing damage)

IT Alkaline earth hydroxides

Glycols, biological studies

Paraffin oils

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(shampoo compns. for decreasing hair combing damage)

IT 56-81-5, Glycerin, biological studies 77-92-9, Citric acid, biological studies 94-13-3, Propylparaben 99-76-3, Methylparaben 139-33-3, Disodium EDTA 1305-62-0, Calcium hydroxide, biological studies 2235-54-3, Ammonium lauryl sulfate 9005-64-5, Polysorbate 20 24938-91-8, Salcare SC95 26161-33-1, Polyquaternium 37 35429-19-7, Polyquaternium 32 39236-46-9, Imidazolidinylurea 81859-24-7, Polyquaternium 10 86752-73-0, Betz 1195 100224-74-6, Guanidine carbonate

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (shampoo compns. for decreasing hair combing damage)

IT 1305-62-0, Calcium hydroxide, biological studies
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (shampoo compns. for decreasing hair combing damage)

RN 1305-62-0 HCAPLUS
 CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)

HO—Ca—OH

L30 ANSWER 11 OF 27 HCAPLUS COPYRIGHT 2002 ACS
 AN 1997:549291 HCAPLUS
 DN 127:152801
 TI Hair coloring compositions
 IN Dias, Louis Carlos; Pullan, Rowena Juliet Flux; Sanger, Alison Jane
 PA Procter & Gamble Company, USA; Dias, Louis Carlos; Pullan, Rowena Juliet Flux; Sanger, Alison Jane
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K007-13
 CC 62-3 (Essential Oils and Cosmetics)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9724105	A1	19970710	WO 1996-US20167	19961217
	W: BR, CN, JP, MX, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CN 1209052	A	19990224	CN 1996-180116	19961217
	EP 918503	A1	19990602	EP 1996-943802	19961217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	BR 9612322	A	19990713	BR 1996-12322	19961217
	JP 11509235	T2	19990817	JP 1996-524403	19961217
	US 6022381	A	20000208	US 1998-91441	19980629
PRAI	GB 1995-26711		19951229		
	WO 1996-US20167		19961217		
AB	A hair coloring compn. comprising: (a) an org. peroxyacid oxidizing agent; and (b) one or more oxidative hair coloring agents. The products can provide excellent hair coloring and in-use efficacy benefits including excellent initial color and good wash fastness in combination with reduced hair damage at lower pH. Example oxidizing agents are peracetic acid, oxidative dyes: p-phenylenediamine; nonoxidative dyes: Basic red 76; chelating agent, EDTA; enzyme horseradish peroxidase; surfactant: cetereth-25; thickener cetyl alc. and antioxidant sodium sulfite.				
ST	hair coloring compn; peroxyacid hair coloring compn				
IT	Alcohols, biological studies Alcohols, biological studies RL: BUU (Biological use, unclassified); MOA (Modifier or additive use); BIOL (Biological study); USES (Uses) (C16-18, ethoxylated; hair coloring compns.)				

IT Alcohols, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(amino; hair coloring compns.)

IT Amines, biological studies.
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(diamines; hair coloring compns.)

IT Hair preparations
(dyes; hair coloring compns.)

IT Antioxidants
Buffers
Oxidizing agents
Surfactants
Thickening agents
(hair coloring compns.)

IT Amino acids, biological studies
Enzymes, biological studies
Hydroxides (inorganic)
Peroxy acids
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hair coloring compns.)

IT Amines, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(polyamines, nonpolymeric; hair coloring compns.)

IT 74-79-3, L-Arginine, biological studies 79-21-0, Peracetic acid
106-50-3, p-Phenylenediamine, biological studies 123-30-8, p-Aminophenol
151-21-3, Sodium lauryl sulfate, biological studies 591-27-5
3058-35-3, Nonaneperoxoic acid 16867-03-1, 2-Amino-3-hydroxypyridine
26381-41-9, Basic brown 16 36574-66-0D, N-coco acyl derivs.
68391-30-0, Basic red 76
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hair coloring compns.)

IT 56-87-1, Lysine, biological studies 60-00-4, EDTA, biological studies
71-00-1, Histidine, biological studies 75-04-7, Ethylamine, biological studies
108-01-0, 2-(Dimethylamino)ethanol 109-76-2,
1,3-Propanediamine 110-91-8, Morpholine, biological studies 111-42-2,
Diethanolamine, biological studies 112-92-5, Stearyl alcohol 121-44-8,
Triethylamine, biological studies 141-43-5, Monoethanolamine, biological studies
142-84-7, Dipropylamine 144-55-8, Sodium bicarbonate,
biological studies 471-34-1, Calcium carbonate, biological studies
497-19-8, Sodium carbonate, biological studies 506-87-6, Ammonium carbonate
584-08-7, Potassium carbonate 1066-33-7, Ammonium bicarbonate 1305-62-0, Calcium hydroxide, biological studies
1309-42-8, Magnesium hydroxide 1310-58-3, Potassium hydroxide,
biological studies 1310-73-2, Sodium hydroxide, biological studies
1336-21-6, Ammonium hydroxide 3983-19-5, Calcium bicarbonate
6000-08-4, HydrOxylysine 7757-83-7, Sodium sulfite 9003-99-0,
Peroxidase 36653-82-4, Cetyl alcohol
RL: BUU (Biological use, unclassified); MOA (Modifier or additive use);
BIOL (Biological study); USES (Uses)
(hair coloring compns.)

IT 1305-62-0, Calcium hydroxide, biological studies 1309-42-8
, Magnesium hydroxide
RL: BUU (Biological use, unclassified); MOA (Modifier or additive use);
BIOL (Biological study); USES (Uses)
(hair coloring compns.)

RN 1305-62-0 HCAPLUS
 CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)

HO—Ca—OH

RN 1309-42-8 HCAPLUS
 CN Magnesium hydroxide (Mg(OH)2) (9CI) (CA INDEX NAME)

HO—Mg—OH

L30 ANSWER 12 OF 27 HCAPLUS COPYRIGHT 2002 ACS
 AN 1997:549287 HCAPLUS
 DN 127:152799
 TI **Hair coloring compositions**
 IN Dias, Louis Carlos; Pullan, Rowena Juliet Flux; Sanger, Alison Jane
 PA Procter & Gamble Company, USA; Dias, Louis Carlos; Pullan, Rowena Juliet Flux; Sanger, Alison Jane
 SO PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K007-13
 CC 62-3 (Essential Oils and **Cosmetics**)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9724107	A1	19970710	WO 1996-US20185	19961217
	W: BR, CN, JP, MX, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 876134	A1	19981111	EP 1996-944867	19961217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	CN 1209053	A	19990224	CN 1996-180117	19961217
	BR 9612388	A	19990713	BR 1996-12388	19961217
	JP 11509236	T2	19990817	JP 1996-524409	19961217
	US 6004355	A	19991221	US 1998-91440	19980629
PRAI	GB 1995-26632		19951229		
	WO 1996-US20185		19961217		

AB A **hair coloring compn.** contains: (a) a water-sol. peroxygen oxidizing agent; (b) an org. peroxyacid oxidizing aid; and (c) one or more oxidative **hair coloring agents**. The products can provide excellent **hair coloring** and in-use efficacy benefits including excellent initial color and good wash fastness in combination with reduced **hair damage** at lower pH. Example oxidizing agent is hydrogen peroxide, peroxyacid precursor: sodium nonanoylebenzenesulfonate, and oxidative dye: p-phenylenediamine.

ST **hair coloring compn;** peroxyacid oxidizing **hair coloring**

IT Alcohols, biological studies
 Alcohols, biological studies
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (C16-18, ethoxylated; **hair coloring compns.**)

IT Alcohols, biological studies
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(amino; hair coloring compns.)

IT Amines, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(diamines; hair coloring compns.)

IT Hair preparations
(dyes; hair coloring compns.)

IT Buffers

Oxidizing agents

Surfactants
(hair coloring compns.)

IT Amino acids, biological studies
Hydroxides (inorganic)
Peroxy acids
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hair coloring compns.)

IT Amines, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(polyamines, nonpolymeric; hair coloring compns.)

IT 77-89-4, Acetyl triethyl citrate 79-21-0, Peracetic acid 106-50-3,
p-Phenylenediamine, biological studies 123-30-8, p-Aminophenol
591-27-5 1066-33-7, Ammonium bicarbonate 1310-58-3, Potassium
hydroxide, biological studies 3058-35-3, Nonaneperoxyic acid
7722-84-1, Hydrogen peroxide, biological studies 16867-03-1,
2-Amino-3-hydroxypyridine 26381-41-9, Basic brown 16 36574-66-0D,
N-coco acyl derivs. 68391-30-0, Basic red 76 91125-43-8, Sodium
nonanoyloxybenzenesulfonate 101482-85-3 173740-85-7 173740-86-8
173740-87-9
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hair coloring compns.)

IT 56-87-1, L-Lysine, biological studies 60-00-4, EDTA, biological studies
71-00-1, L-Histidine, biological studies 74-79-3, L-Arginine, biological
studies 75-04-7, Ethylamine, biological studies 108-01-0,
Dimethylaminoethanol 109-76-2, 1,3-Propanediamine 110-91-8,
Morpholine, biological studies 111-40-0, Diethylenetriamine 111-42-2,
Diethanolamine, biological studies 112-92-5, Stearyl alcohol 121-44-8,
Triethylamine, biological studies 141-43-5, Monoethanolamine, biological
studies 142-84-7, Dipropylamine 144-55-8, Sodium bicarbonate,
biological studies 151-21-3, Sodium lauryl sulfate, biological studies
471-34-1, Calcium carbonate, biological studies 497-19-8, Sodium
carbonate, biological studies 506-87-6, Ammonium carbonate 584-08-7,
Potassium carbonate 1305-62-0, Calcium hydroxide, biological
studies 1309-42-8, Magnesium hydroxide 1310-73-2, Sodium
hydroxide, biological studies 1336-21-6, Ammonium hydroxide 3983-19-5,
Calcium bicarbonate 6000-08-4, Hydroxyllysine 7664-38-2, Phosphoric
acid, biological studies 7757-83-7, Sodium sulfite 9003-99-0,
Peroxidase 36653-82-4, Cetyl alcohol
RL: BUU (Biological use, unclassified); MOA (Modifier or additive use);
BIOL (Biological study); USES (Uses)
(hair coloring compns.)

IT 1305-62-0, Calcium hydroxide, biological studies 1309-42-8
, Magnesium hydroxide
RL: BUU (Biological use, unclassified); MOA (Modifier or additive use);
BIOL (Biological study); USES (Uses)
(hair coloring compns.)

RN 1305-62-0 HCPLUS

CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)

HO—Ca—OH

RN 1309-42-8 HCPLUS
 CN Magnesium hydroxide (Mg(OH)2) (9CI) (CA INDEX NAME)

HO—Mg—OH

L30 ANSWER 13 OF 27 HCPLUS COPYRIGHT 2002 ACS
 AN 1997:549285 HCPLUS
 DN 127:166522
 TI **Hair coloring compositions**
 IN Dias, Louis Carlos; Murray, Pauline; Pullan, Rowena Juliet Flux; Sanger, Alison Jane
 PA Procter & Gamble Company, USA; Dias, Louis Carlos; Murray, Pauline; Pullan, Rowena Juliet Flux; Sanger, Alison Jane
 SO PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K007-13
 CC 62-3 (Essential Oils and **Cosmetics**)
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9724106	A1	19970710	WO 1996-US20170	19961217
	W: BR, CN, JP, MX, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 879045	A1	19981125	EP 1996-944861	19961217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	CN 1209055	A	19990224	CN 1996-180118	19961217
	CN 1209054	A	19990224	CN 1996-180119	19961217
	BR 9612328	A	19990302	BR 1996-12328	19961217
	JP 3045400	B2	20000529	JP 1997-524405	19961217
	JP 11501947	T2	19990216		
PRAI	GB 1995-26633	A	19951229		
	WO 1996-US20170	W	19961217		
AB	A hair coloring compn. comprising: (a) a water-sol. peroxygen bleach; (b) a bleaching aid selected from org. peroxyacid bleach precursors and/or preformed org. peroxyacids; (c) one or more hair coloring agents. The products can provide excellent hair coloring and in-use efficacy benefits including excellent initial color and good wash fastness in combination with reduced hair damage at lower pH. Example peroxygen bleach is hydrogen peroxide, peroxyacid precursor is sodium nonanoylbenzenesulfonate, and oxidative dye p-phenylenediamine.				
ST	hair coloring compn; peroxy bleach hair coloring compn				
IT	Alcohols, biological studies RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (amino; hair coloring compns.)				
IT	Amines, biological studies RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)				

(diamines; hair coloring compns.)
IT Hair preparations
(dyes; hair coloring compns.)
IT Bleaching agents
Buffers
Surfactants
Swelling agents
(hair coloring compns.)
IT Amino acids, biological studies
Hydroxides (inorganic)
Peroxy acids
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hair coloring compns.)
IT 77-89-4, Acetyl triethyl citrate 79-21-0, Peracetic acid 108-46-3,
Resorcinol, biological studies 123-30-8, p-Aminophenol 591-27-5
3058-35-3, Nonaneperoxyic acid 7722-84-1, Hydrogen peroxide, biological
studies 26381-41-9, Basic brown 16 68391-30-0, Basic red 76
91125-43-8, Sodium nonanoyloxybenzenesulfonate
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hair coloring compns.)
IT 56-87-1, L-Lysine, biological studies 60-00-4, Edta, biological studies
71-00-1, L-Histidine, biological studies 74-79-3, L-Arginine, biological
studies 75-04-7, Ethylamine, biological studies 106-50-3,
p-Phenylenediamine, biological studies 108-01-0, Dimethylaminoethanol
109-76-2, 1,3-Propanediamine 110-91-8, Morpholine, biological studies
111-40-0, Diethylenetriamine 111-42-2, Diethanolamine, biological
studies 121-44-8, Triethylamine, biological studies 141-43-5,
Monoethanolamine, biological studies 142-84-7, Dipropylamine 144-55-8,
Sodium bicarbonate, biological studies 151-21-3, Sodium lauryl sulfate,
biological studies 471-34-1, Calcium carbonate, biological studies
497-19-8, Sodium carbonate, biological studies 506-87-6, Ammonium
carbonate 584-08-7, Potassium carbonate 1066-33-7, Ammonium
bicarbonate 1305-62-0, Calcium hydroxide, biological studies
1309-42-8, Magnesium hydroxide 1310-58-3, Potassium hydroxide,
biological studies 1310-73-2, Sodium hydroxide, biological studies
1336-21-6, Ammonium hydroxide 3983-19-5, Calcium bicarbonate
6000-08-4, HydrOxylysine 7664-38-2, Phosphoric acid, biological studies
9003-99-0, Peroxidase 26027-38-3, Nonoxynol-9 36574-66-0D, N-coco acyl
derivs. 101482-85-3 173740-85-7 173740-86-8 173740-87-9
193487-42-2, Aculyn 44
RL: BUU (Biological use, unclassified); MOA (Modifier or additive use);
BIOL (Biological study); USES (Uses)
(hair coloring compns.)
IT 1305-62-0, Calcium hydroxide, biological studies 1309-42-8
, Magnesium hydroxide
RL: BUU (Biological use, unclassified); MOA (Modifier or additive use);
BIOL (Biological study); USES (Uses)
(hair coloring compns.)
RN 1305-62-0 HCPLUS
CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)



RN 1309-42-8 HCPLUS
CN Magnesium hydroxide (Mg(OH)2) (9CI) (CA INDEX NAME)

HO—Mg—OH

L30 ANSWER 14 OF 27 HCAPLUS COPYRIGHT 2002 ACS
 AN 1997:547307 HCAPLUS
 DN 127:152800
 TI **Hair bleaching compositions**
 IN Dias, Louis Carlos; Murray, Pauline; Pullan, Rowena Juliet Flux; Sanger, Alison Jane
 PA Procter & Gamble Company, USA; Dias, Louis Carlos; Murray, Pauline; Pullan, Rowena Juliet Flux; Sanger, Alison Jane
 SO PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K007-135
 CC 62-3 (Essential Oils and **Cosmetics**)
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9724108	A1	19970710	WO 1996-US20169	19961217
	W: BR, CN, JP, MX, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 869769	A1	19981014	EP 1996-944860	19961217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	CN 1209055	A	19990224	CN 1996-180118	19961217
	CN 1209054	A	19990224	CN 1996-180119	19961217
	BR 9612384	A	19990713	BR 1996-12384	19961217
	JP 2002509519	T2	20020326	JP 1997-524404	19961217
PRAI	GB 1995-26633	A	19951229		
	WO 1996-US20169	W	19961217		
AB	A hair bleaching compn. comprising: (a) a water-sol. peroxygen bleach; and (b) a bleaching aid selected from org. peroxyacid bleach precursors and/or preformed org. peroxyacids. The products can provide excellent hair bleaching and in-use efficacy benefits including reduced hair damage at lower pH.				
ST	hair bleach formulation				
IT	Hair preparations (bleaches; hair bleaching compns.)				
IT	Buffers Surfactants Swelling agents (hair bleaching compns.)				
IT	Alkali metal hydroxides Alkaline earth hydroxides Enzymes, biological studies RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (hair bleaching compns.)				
IT	Peroxy acids RL: BUU (Biological use, <u>unclassified</u>); BIOL (Biological study); USES (Uses) (org.; hair bleaching compns.)				
IT	75-04-7, Ethylamine, biological studies 121-44-8, Triethylamine, biological studies 142-84-7, Dipropylamine 1336-21-6, Ammonium hydroxide 7664-38-2, Phosphoric acid, biological studies RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)				

(buffer; hair bleaching compns.)

IT 56-87-1, Lysine, biological studies 71-00-1, Histidine, biological studies 74-79-3, Arginine, biological studies 77-89-4, Acetyl triethylcitrate 79-21-0, Peracetic acid 108-01-0, Dimethylaminoethanol 109-76-2, 1,3-Diaminopropane 110-91-8, Morpholine, biological studies 111-40-0, Diethylenetriamine 111-42-2, Diethanolamine, biological studies 141-43-5, Ethanolamine, biological studies 144-55-8, Sodium hydrogen carbonate, biological studies 471-34-1, Calcium carbonate, biological studies 497-19-8, Sodium carbonate, biological studies 506-87-6, Ammonium carbonate 584-08-7, Potassium carbonate 1066-33-7, Ammonium hydrogen carbonate 1190-94-9, Hydroxylysine 1305-62-0, Calcium hydroxide, biological studies 1309-42-8, Magnesium hydroxide 1310-58-3, Potassium hydroxide, biological studies 1310-73-2, Sodium hydroxide, biological studies 3058-35-3, Pernonanoic acid 3983-19-5, Calcium hydrogen carbonate 10543-57-4, Tetraacetyl ethylene diamine 101482-85-3--173740-85-7 173740-87-9
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(hair bleaching compns.)

IT 1305-62-0, Calcium hydroxide, biological studies 1309-42-8, Magnesium hydroxide
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(hair bleaching compns.)

RN 1305-62-0 HCPLUS

CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)

HO—Ca—OH

RN 1309-42-8 HCPLUS

CN Magnesium hydroxide (Mg(OH)2) (9CI) (CA INDEX NAME)

HO—Mg—OH

L30 ANSWER 15 OF 27 HCPLUS COPYRIGHT 2002 ACS

AN 1997:411007 HCPLUS

DN 127:99524

TI Hair strengthening composition containing cationic polyquaternary polymers

IN Syed, Ali N.; Ahmad, Kaleem

PA Avlon Industries, Inc., USA

SO U.S., 9 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K007-09

NCL 424070170

CC 62-3 (Essential Oils and Cosmetics)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5639449	A	19970617	US 1994-292107	19940817
	US 5641478	A	19970624	US 1995-493491	19950622
	ZA 9509298	A	19970505	ZA 1995-9298	19951103
PRAI	US 1994-292107	A3	19940817		

AB A hair strengthening **relaxing compn.**
comprising a cationic polyquaternary polymer that is the product of a condensation reaction of a lower dialkylamine (C2-3), a difunctional epoxy compd. and a third reactant selected from the group consisting of ammonia, primary amines, alkylene diamines having two to six carbon atoms, and polyamines; and a high-alky. **hair relaxing agent.** A **hair relaxer** contained propylene glycol 2.00, 50% sodium hydroxide 4.50, PEG-50 lanolin 0.49, Betz polymer 1195 2.00, petrolatum 12.00, mineral oil 17.00, emulsifier 10.00, Laneth-15 0.98, and water 53.03%.

ST hair strengthening **compn** cationic polyquaternary polymer

IT Amines, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study) (diamines, reaction products with dialkylamines and epoxy compds.; **hair strengthening compn.** contg. cationic polyquaternary polymers)

IT Alkali metal **hydroxides**
Alkaline earth **hydroxides**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**hair strengthening compn.** contg. cationic polyquaternary polymers)

IT Quaternary ammonium compounds, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**hydroxides; hair strengthening compn.** contg. cationic polyquaternary polymers)

IT Amines, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study) (polyamines, nonpolymeric, reaction products with dialkylamines and epoxy compds.; **hair strengthening compn.** contg. cationic polyquaternary polymers)

IT Quaternary ammonium compounds, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(polymers; **hair strengthening compn.** contg. cationic polyquaternary polymers)

IT Amines, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study) (primary, reaction products with dialkylamines and epoxy compds.; **hair strengthening compn.** contg. cationic polyquaternary polymers)

IT Hair preparations
(straighteners; **hair strengthening compn.** contg. cationic polyquaternary polymers)

IT 7664-41-7D, Ammonia, reaction products with dialkylamines and epoxy compds., biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**hair strengthening compn.** contg. cationic polyquaternary polymers)

IT 113-00-8, Guanidine 1305-62-0, Calcium hydroxide, biological studies 1310-73-2, Sodium hydroxide, biological studies 26062-79-3, Merquat 100 42751-79-1 64120-25-8, Guanidine hydroxide 68039-13-4, Polycare 133 86752-73-0, Betz 1195 100224-74-6, Guanidine carbonate
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(**hair strengthening compn.** contg. cationic polyquaternary polymers)

IT 1305-62-0, Calcium hydroxide, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (hair strengthening compn. contg. cationic polyquaternary polymers)

RN 1305-62-0 HCAPLUS
 CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)

HO—Ca—OH

L30 ANSWER 16 OF 27 HCAPLUS COPYRIGHT 2002 ACS
 AN 1997:155151 HCAPLUS
 DN 126:162344
 TI Antibacterial/bactericidal/antiseptic agent, dermatologic preparation, and detergent **composition**
 IN Saito, Yoshinobu; Kishi, Nobuyuki; Kita, Katsuhito; Hirano, Natsue; Nishina, Tetsuo
 PA P and Pf Co., Ltd., Japan; Saito, Yoshinobu; Kishi, Nobuyuki; Kita, Katsuhito; Hirano, Natsue; Nishina, Tetsuo
 SO PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 IC ICM A61K031-12
 ICS A61K031-28; A61L002-16; A01N031-06
 CC 63-8 (Pharmaceuticals)
 Section cross-reference(s): 62

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9702025	A1	19970123	WO 1996-JP920	19960401
	W: CN, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 835655	A1	19980415	EP 1996-907767	19960401
	R: DE, FR, GB, IT				
	CN 1189099	A	19980729	CN 1996-195108	19960401
	US 6025312	A	20000215	US 1997-894020	19970723
PRAI	JP 1995-188545		19950630		
	JP 1995-344461		19951204		
	WO 1996-JP920		19960401		
AB	An antibacterial/bactericidal/antiseptic agent, a dermatol. prep. and a detergent compn. each contains, an aluminum salt of hinokitiol or/and a complex compd. of hinokitiol with an aluminum compd. as the active ingredient. The use of hinokitiol in the form of the above salt or complex serves to dispel the thermal, optical and chem. instabilities inherent in hinokitiol and to stabilize hinokitiol preps. during the prodn. and storage thereof.				
ST	hinokitiol aluminum bactericide cosmetic; dermatol prep hinokitiol aluminum; detergent hinokitiol aluminum				
IT	Antibacterial agents Bath preparations Detergents (antibacterial/bactericidal/antiseptic agent, dermatol. prep., and detergent compn. contg. hinokitiol aluminum salts or complexes)				
IT	Shampoos (body; antibacterial/bactericidal/antiseptic agent, dermatol. prep., and detergent compn. contg. hinokitiol aluminum salts or				

complexes)

IT Cosmetics
(skin; antibacterial/bactericidal/antiseptic agent, dermatol. prepn., and detergent **compn.** contg. hinokitiol aluminum salts or **complexes**)


IT Hair conditioners
(tonics; antibacterial/bactericidal/antiseptic agent, dermatol. prepn., and detergent **compn.** contg. hinokitiol aluminum salts or **complexes**)

IT 499-44-5D, Hinokitiol, aluminum salts or **complexes** 1344-28-1D, Aluminum oxide (Al2O3), hinokitiol **complexes** 21645-51-2D, Aluminum hydroxide, hinokitiol **complexes** 186905-95-3
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibacterial/bactericidal/antiseptic agent, dermatol. prepn., and detergent **compn.** contg. hinokitiol aluminum salts or **complexes**)

IT 21645-51-2D, Aluminum hydroxide, hinokitiol **complexes**
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibacterial/bactericidal/antiseptic agent, dermatol. prepn., and detergent **compn.** contg. hinokitiol aluminum salts or **complexes**)

RN 21645-51-2 HCAPLUS

CN Aluminum hydroxide (Al(OH)3) (9CI) (CA INDEX NAME)



L30 ANSWER 17 OF 27 HCAPLUS COPYRIGHT 2002 ACS

AN 1996:544080 HCAPLUS

DN 125:176979

TI Novel **hair relaxer compositions** based on lithium salts

IN Cowsar, Donald R.

PA Carsons Products Company, USA

SO PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K007-09

CC 62-3 (Essential Oils and **Cosmetics**)

Section cross-reference(s): 78

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9621418	A1	19960718	WO 1996-US18	19960111
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN				
	US 5609859	A	19970311	US 1995-373940	19950113
	CA 2210198	AA	19960718	CA 1996-2210198	19960111

AU 9646506	A1 19960731	AU 1996-46506	19960111
ZA 9600214	A 19970711	ZA 1996-214	19960111
BR 9607180	A 19971111	BR 1996-7180	19960111
EP 809481	A1 19971203	EP 1996-902048	19960111
R: BE, FR, GB, NL			
US 5849277	A 19981215	US 1996-698969	19960816
PRAI US 1995-373940	A 19950113		
WO 1996-US18	W 19960111		

AB Methods for prep. hair relaxer compns.

comprise a lithium salt and an alk. earth hydroxide, wherein the lithium salt is in molar excess to the alk. earth hydroxide. Compns., kits contg. the compns., and methods for using the compns. are also disclosed.

ST lithium salt hydroxide hair relaxer

IT Alkaline earth hydroxides

RL: BUU (Biological use, unclassified); RCT (Reactant); BIOL (Biological study); USES (Uses)
(hair relaxer compns. based on lithium salts)

IT Hair preparations

(relaxers, hair relaxer compns.
based on lithium salts)

IT 497-19-8, Sodium carbonate, biological studies 554-13-2, Lithium carbonate 584-08-7, Potassium carbonate 1305-62-0, Calcium hydroxide, biological studies 1305-78-8, Calcium oxide, biological studies 1310-58-3, Potassium hydroxide, biological studies 1310-65-2, Lithium hydroxide 7439-93-2D, Lithium, salts 10377-48-7, Lithium sulfate 10377-52-3, Lithium phosphate 17194-00-2, Barium hydroxide 18480-07-4, Strontium hydroxide

RL: BUU (Biological use, unclassified); RCT (Reactant); BIOL (Biological study); USES (Uses)
(hair relaxer compns. based on lithium salts)

IT 1305-62-0, Calcium hydroxide, biological studies
17194-00-2, Barium hydroxide 18480-07-4, Strontium hydroxide

RL: BUU (Biological use, unclassified); RCT (Reactant); BIOL (Biological study); USES (Uses)
(hair relaxer compns. based on lithium salts)

RN 1305-62-0 HCPLUS

CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)

HO—Ca—OH

RN 17194-00-2 HCPLUS

CN Barium hydroxide (Ba(OH)2) (9CI) (CA INDEX NAME)

HO—Ba—OH

RN 18480-07-4 HCPLUS

CN Strontium hydroxide (Sr(OH)2) (9CI) (CA INDEX NAME)

HO—Sr—OH

L30 ANSWER 18 OF 27 HCAPLUS COPYRIGHT 2002 ACS
AN 1996:71445 HCAPLUS
DN 124:155649
TI Conditioning and straightening hair relaxer
IN Patel, Manilal M.
PA Luster Products, Inc., USA
SO U.S., 5 pp. Cont. of U.S. Ser.No. 210,133, abandoned.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K007-09
 ICS A61K007-07
NCL 424070200
CC 62-3 (Essential Oils and Cosmetics)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5476650	A	19951219	US 1995-402301	19950309
PRAI	US 1994-210133		19940317		

AB A hair relaxing compn. used in high alk. conditions comprising at least one active hair relaxer ingredient, moisturizers, emollients, and emulsifier, with polymethacrylamidopropyltrimonium chloride included in the formula. A hair relaxing system was prep'd. contg. cetearyl alc. and Ceteareth 20 10.00, cetyl alc. 1.00, PEG-75 lanolin 0.50, mineral oil 24.00, petrolatum 10.00, DEA oleth-10 phosphate 0.50, water 44.45, propylene glycol 3.0, LiOH.cntdot.H2O 2.75, Ca(OH)2 1.80, and polymethacrylamidopropyltrimonium chloride 2.00 wt.%, resp.
ST polymethacrylamidopropyltrimonium chloride hair straightening conditioner; hair relaxer conditioning straightening polymethacrylamidopropyltrimonium-chloride
IT Alcohols, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (cetearyl; conditioning and straightening hair relaxer compns. contg. polymethacrylamidopropyltrimonium chloride)
IT Paraffin oils
Petrolatum
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (conditioning and straightening hair relaxer compns. contg. polymethacrylamidopropyltrimonium chloride)
IT Alcohols, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (C16-18, ethoxylated, conditioning and straightening hair relaxer compns. contg. polymethacrylamidopropyltrimonium chloride)
IT Hair preparations
 (conditioners, straighteners, conditioning and straightening hair relaxer compns. contg. polymethacrylamidopropyltrimonium chloride)
IT Lanolin
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (ethoxylated, conditioning and straightening hair relaxer compns. contg. polymethacrylamidopropyltrimonium chloride)

ium chloride)

IT Hair preparations
 (relaxers, conditioning and straightening hair
 relaxer compns. contg. polymethacrylamidopropyltrimonium
 chloride)

IT 57-55-6, Propylene glycol, biological studies 1305-62-0, Calcium
 hydroxide (Ca(OH)2), biological studies 1310-65-2, Lithium hydroxide
 (LiOH) 1310-73-2, Sodium hydroxide, biological studies 36653-82-4,
 Cetyl alcohol 68039-13-4 173447-16-0
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
 (Uses)
 (conditioning and straightening hair relaxer
 compns. contg. polymethacrylamidopropyltrimonium chloride)

IT 1305-62-0, Calcium hydroxide (Ca(OH)2), biological studies
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
 (Uses)
 (conditioning and straightening hair relaxer
 compns. contg. polymethacrylamidopropyltrimonium chloride)

RN 1305-62-0 HCAPLUS

CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)

HO—Ca—OH

L30 ANSWER 19 OF 27 HCAPLUS COPYRIGHT 2002 ACS
 AN 1995:756259 HCAPLUS
 DN 123:142668
 TI Cation-complexed polysaccharides
 IN Barnum, Paquita E.; Majewicz, Thomas G.
 PA Hercules Inc., USA
 SO Can. Pat. Appl., 57 pp.
 CODEN: CPXXEB
 DT Patent
 LA English
 IC ICM C08B037-00
 ICS C08B011-12; C08B031-12; A61K031-715; A23L001-308
 CC 18-7 (Animal Nutrition)
 Section cross-reference(s): 17, 33, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2128160	AA	19950117	CA 1994-2128160	19940715
	FI 9403296	A	19950117	FI 1994-3296	19940711
	NO 9402620	A	19950117	NO 1994-2620	19940712
	HU 75240	A2	19970528	HU 1994-2102	19940714
	CZ 288879	B6	20010912	CZ 1994-1702	19940714
	AU 9467502	A1	19950127	AU 1994-67502	19940715
	AU 675542	B2	19970206		
	JP 07090002	A2	19950404	JP 1994-163665	19940715
	EP 648495	A2	19950419	EP 1994-111053	19940715
	EP 648495	B1	20000105		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, PT, SE				
	AT 188380	E	20000115	AT 1994-111053	19940715
	ES 2140482	T3	20000301	ES 1994-111053	19940715
	CN 1104890	A	19950712	CN 1994-116163	19940716
	BR 9402851	A	19950613	BR 1994-2851	19940718
PRAI	US 1993-93231	A	19930716		
AB	An ingestible compn. comprises at list one water-insol., cation-				

complexed anionic polysaccharide dispersed in an aq. medium. The compn. has a low viscosity and is heat sterilizable. The polysaccharide of the present invention cause no or minor increase of viscosity of liqs. contg. proteins, peptides or amino acids. The compns. are useful as an antidiarrheal, a nutritional means of improving gastrointestinal function including bowel function and increasing absorption of org. and inorg. nutrients and water. A water-insol., cation-**complexed** anionic polysaccharide is prep'd. by wetting a starting anionic-polysaccharide with water to a total solids content of about 30-70%, adding a cation and then milling. A low viscosity, feeding compn. provides an individual's requirements for carbohydrates, proteins, lipids, vitamins, minerals and at least one substantially water-insol., cation-**complexed** anionic polysaccharide in an aq. medium. This same compn. may be prep'd. in a dehydrated state and then subsequently rehydrated when ready for use.

ST anionic polysaccharide cation **complex** antidiarrheal feeding
IT Cations

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**complexes** with anionic polysaccharides; ingestible liq. compns. contg. water-insol. cation-**complexed** anionic polysaccharides)

IT Digestive tract

(ingestible liq. compns. contg. water-insol. cation-**complexed** anionic polysaccharides)

IT Amino acids, biological studies

Beverages

Dietary fiber

Fatty acids, biological studies

Flaxseed

Mineral elements

Okra

Peptides, biological studies

Proteins, biological studies

Vitamins

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ingestible liq. compns. contg. water-insol. cation-**complexed** anionic polysaccharides)

IT Diarrhea

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhibitors; ingestible liq. compns. contg. water-insol. cation-**complexed** anionic polysaccharides)

IT Polysaccharides, biological studies

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(acidic, **complexes**; ingestible liq. compns. contg. water-insol. cation-**complexed** anionic polysaccharides)

IT Polysaccharides, biological studies

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(carboxylates, **complexes**; ingestible liq. compns. contg. water-insol. cation-**complexed** anionic polysaccharides)

IT Polysaccharides, biological studies

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**complexes**, with cations; ingestible liq. compns. contg. water-insol. cation-**complexed** anionic polysaccharides)

IT Nutrients

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enteral, ingestible liq. **compns.** contg. water-insol. cation-**complexed** anionic polysaccharides)

IT Pharmaceutical dosage forms
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enteric, ingestible liq. **compns.** contg. water-insol. cation-**complexed** anionic polysaccharides)

IT Polysaccharides, biological studies
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphates, **complexes**; ingestible liq. **compns.**
contg. water-insol. cation-**complexed** anionic polysaccharides)

IT Alkali metal compounds
Alkaline earth compounds
Transition metal compounds
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(salts, **complexes**; ingestible liq. **compns.** contg.
water-insol. cation-**complexed** anionic polysaccharides)

IT Polysaccharides, biological studies
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sulfates, **complexes**; ingestible liq. **compns.**
contg. water-insol. cation-**complexed** anionic polysaccharides)

IT 299-28-5D, Calcium gluconate, **complexes** with anionic polysaccharides 1305-62-0D, Calcium hydroxide, **complexes** with anionic polysaccharides 4075-81-4D, Calcium propionate, **complexes** with anionic polysaccharides 5743-27-1D, Calcium ascorbate, **complexes** with anionic polysaccharides 7429-90-5D, Aluminum, **complexes** with anionic polysaccharides 7439-89-6D, Iron, **complexes** with anionic polysaccharides 7439-95-4D, Magnesium, **complexes** with anionic polysaccharides 7439-96-5D, Manganese, **complexes** with anionic polysaccharides 7440-09-7D, Potassium, **complexes** with anionic polysaccharides 7440-23-5D, Sodium, **complexes** with anionic polysaccharides 7440-50-8D, Copper, **complexes** with anionic polysaccharides 7440-66-6D, Zinc, **complexes** with anionic polysaccharides 7440-70-2D, Calcium, **complexes** with anionic polysaccharides 7487-88-9D, Magnesium sulfate, **complexes** with anionic polysaccharides 7646-85-7D, Zinc chloride, **complexes** with anionic polysaccharides 7693-13-2D, Calcium citrate, **complexes** with anionic polysaccharides 7758-94-3D, Ferrous chloride, **complexes** with anionic polysaccharides 7778-18-9D, Calcium sulfate, **complexes** with anionic polysaccharides 8063-16-9D, Psyllium, **complexes** with cations 9000-01-5D, Arabic gum, **complexes** with cations 9000-28-6D, Ghatti-gum, **complexes** with cations 9000-36-6D, Karaya gum, **complexes** with cations 9000-65-1D, Tragacanth, **complexes** with cations 9000-69-5D, Pectin, **complexes** with cations 9004-32-4D, **complexes** with cations 9004-61-9D, Hyaluronic acid, **complexes** with cations 9005-25-8D, Starch, phosphated, **complexes** with cations 9005-38-3D, Sodium alginate, **complexes** with cations 9005-49-6D, Heparin, **complexes** with cations 9007-28-7D, Chondroitin sulfate, **complexes** with cations 9012-72-0D, Glucan, phosphated, **complexes** with cations 9032-43-3D, Cellulose sulfate, **complexes** with cations 9050-30-0D, Heparan sulfate, **complexes** with cations 9056-36-4D, Keratan sulfate, **complexes** with cations 9057-06-1D, CM-starch,

complexes with cations 10043-52-4D, Calcium chloride,
complexes with anionic polysaccharides 10103-46-5D, Calcium
phosphate, **complexes** with anionic polysaccharides 11114-20-8D,
.kappa.-Carrageenan, **complexes** with cations 11138-66-2D,
Xanthan, **complexes** with cations 24967-94-0D, Dermatan sulfate,
complexes with cations 28633-45-6D, Ferric citrate,
complexes with anionic polysaccharides 51198-15-3D, CM-guar,
complexes with cations 69992-87-6D, Keratan,
complexes with cations 71010-52-1D, Gellan gum,
complexes with cations

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ingestible liq. compns. contg. water-insol. cation-
complexed anionic polysaccharides)

IT 1305-62-0D, Calcium hydroxide, **complexes** with anionic
polysaccharides

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ingestible liq. compns. contg. water-insol. cation-
complexed anionic polysaccharides)

RN 1305-62-0 HCPLUS

CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)

HO—Ca—OH

L30 ANSWER 20 OF 27 HCPLUS COPYRIGHT 2002 ACS

AN 1995:452277 HCPLUS

DN 122:196539

TI Hair relaxer compositions containing strong
base and alkaline earth metal hydroxides

IN Cowsar, Donald R.; Adair, Tony R.

PA Aminco, Inc., USA

SO PCT Int. Appl., 89 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K007-09

ICS A61K007-08

CC 62-3 (Essential Oils and Cosmetics)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9503031	A1	19950202	WO 1994-US7813	19940719
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
	RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US	5565216	A	19961015	US 1993-93956	19930721
ZA	9405081	A	19950123	ZA 1994-5081	19940713
CA	2144971	AA	19950202	CA 1994-2144971	19940719
AU	9472206	A1	19950220	AU 1994-72206	19940719
EP	660699	A1	19950705	EP 1994-921504	19940719
EP	660699	B1	20001025		
	R: BE, DE, ES, FR, GB, IT, NL, SE				
BR	9405526	A	19990908	BR 1994-5526	19940719
ES	2154296	T3	20010401	ES 1994-921504	19940719

PRAI US 1993-93956 A 19930721
WO 1994-US7813 W 19940719

AB A two-component **hair relaxer** system comprises (a) a first component comprising a cream base contg. a water-sol. salt of a relatively strong base with an anion capable of being pptd. by an alk. earth metal ion under highly alk. conditions, and (b) a second, sep. component, which is substantially free of water, and contg. an alk. material having an alk. earth metal ion which forms a ppt. with the anion when the first component and second component are mixed. A **hair relaxer** system contained Cosmowax J 12.00, petrolatum 10.00, light mineral oil 10.00, Generol 122E-5 (PEG-5 soya sterol) 1.00, water 54.7985, Flulian AWS 3.00, guanidine carbonate 7.40, succinic acid 0.3, thiazole yellow G 0.0015, Crodafos SG 1.50, in the first component which was a cream base having pH = 10.1 and propylene glycol 51.0, silica 4.0, Ca(OH)2 37.0, CaO 6.0, TiO2 2.0 in the second component which was an activator lotion.

ST **hair relaxer** alk earth metal hydroxide; base
hair relaxer; calcium hydroxide guanidine carbonate
hair relaxer

IT Alkaline earth **hydroxides**

Alkaline earth oxides

Amidines

Carboxylic acids, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
(Uses)

(**hair relaxer compns.** contg. strong base
and alk. earth metal **hydroxides**)

IT Acids, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
(Uses)

(heterocyclic; **hair relaxer compns.**

contg. strong base and alk. earth metal **hydroxides**)

IT Bases, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
(Uses)

(strong; **hair relaxer compns.** contg.

strong base and alk. earth metal **hydroxides**)

IT Carboxylic acids, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
(Uses)

(aliph., **hair relaxer compns.** contg.

strong base and alk. earth metal **hydroxides**)

IT Carboxylic acids, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
(Uses)

(aliph., cyclic, **hair relaxer compns.**

contg. strong base and alk. earth metal **hydroxides**)

IT Carboxylic acids, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
(Uses)

(aryl, **hair relaxer compns.** contg. strong

base and alk. earth metal **hydroxides**)

IT Carboxylic acids, biological studies

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
(Uses)

(di-, **hair relaxer compns.** contg. strong

base and alk. earth metal **hydroxides**)

IT Hair preparations

(**relaxers**, **hair relaxer compns.**

contg. strong base and alk. earth metal **hydroxides**)

IT 50-21-5, Lactic acid, biological studies 56-81-5, 1,2,3-Propanetriol, biological studies 56-86-0, L-Glutamic acid, biological studies 57-55-6, 1,2-Propanediol, biological studies 60-35-5, Acetamide, biological studies 107-41-5, Hexylene glycol 110-15-6, Succinic acid, biological studies 110-16-7, 2-Butenedioic acid (Z)-, biological studies 113-00-8, Guanidine 144-62-7, Oxalic acid, biological studies 471-29-4, n-Methyl guanidine 1305-62-0, Calcium hydroxide, biological studies 1305-78-8, Calcium oxide, biological studies 7664-38-2, Phosphoric acid, biological studies 7664-93-9, Sulfuric acid, biological studies 25265-75-2, Butylene glycol 44592-85-0 100224-74-6, Guanidine carbonate
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (hair relaxer compns. contg. strong base and alk. earth metal hydroxides)

IT 1305-62-0, Calcium hydroxide, biological studies
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (hair relaxer compns. contg. strong base and alk. earth metal hydroxides)

RN 1305-62-0 HCAPLUS
 CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)

HO—Ca—OH

L30 ANSWER 21 OF 27 HCAPLUS COPYRIGHT 2002 ACS
 AN 1993:575751 HCAPLUS
 DN 119:175751
 TI in vitro model for eye and skin irritation testing
 IN Osborne, Rosemarie; Perkins, Mary Ann; Roberts, Deirdre Anne
 PA Procter and Gamble Co., USA
 SO PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM G01N033-50
 CC 4-1 (Toxicology)
 Section cross-reference(s): 62

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9317336	A1	19930902	WO 1993-US737	19930127
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	AU 9335956	A1	19930913	AU 1993-35956	19930127
	US 6020148	A	20000201	US 1997-877963	19970618
PRAI	US 1992-838594		19920219		
	WO 1993-US737		19930127		
	US 1993-115901		19930901		
	US 1995-378897		19950126		
AB	A technique is disclosed for testing of ocular and dermal irritants. The process involves the topical application of, liq., solid, granular, or gel-like materials (e.g. cosmetics) to a cell culture and then evaluating the cytotoxicity of the material. Cell cultures of human skin without a stratum corneum and having a histol. similarity to the eyes are used.				

Irritation is evaluated by measuring cell viability using an MTT assay (based on the redn. of a tetrazolium dye by functional mitochondria) or by testing for **release** of LDH or PGE2. A unique method of applying test materials which are not water-sol. is also described. The methodol. of the invention was applied to strong (e.g. NaOH, dish detergent), mild to moderate (e.g. laundry detergent, skin care cream), and innocuous to slight (e.g. liq. fabric softener, toothpaste) irritant test materials.

ST irritant eye skin bioassay; cosmetic irritant bioassay

IT Irritants
(bioassay for, of skin or eye)

IT Textiles
(cleaning and care products for, irritancy of, for skin or eye, bioassay for evaluation of)

IT Coloring materials
(cosmetic, irritancy of, for skin or eye, bioassay for evaluation of)

IT Bioassay
(for skin or eye irritant)

IT Softening agents
(for textiles, irritancy of liq., for skin or eye, bioassay for evaluation of)

IT Animal tissue culture
(in irritant of skin or eye evaluation)

IT Cosmetics
Cream
Dentifrices
Emulsions
Pastes
Powders
Sunscreens
Surfactants
(irritancy of, for skin or eye, bioassay for evaluation of)

IT Eye, toxic chemical and physical damage
Skin, toxic chemical and physical damage
(irritant of, bioassay for)

IT Gels
(products like, irritancy of, for skin or eye, bioassay for evaluation of)

IT Fibroblast
(without stratum corneum, in bioassay for irritant evaluation)

IT Detergents
(cleaning **compns.**, irritancy of, for skin or eye, bioassay for evaluation of)

IT Cosmetics
(cleansing, irritancy of, for skin or eye, bioassay for evaluation of)

IT Perfumes
(colognes, irritancy of, for skin or eye, bioassay for evaluation of)

IT Dyes
(cosmetic, irritancy of, for skin or eye, bioassay for evaluation of)

IT Cosmetics
(creams, irritancy of, for skin or eye, bioassay for evaluation of)

IT Detergents
(dishwashing, irritancy of, for skin or eye, bioassay for evaluation of)

IT Hair preparations
(dyes, irritancy of, for skin or eye, bioassay for evaluation of)

IT Skin
(**keratinocyte**, without stratum corneum, in bioassay for irritant evaluation)

IT Detergents
(laundry, irritancy of, for skin or eye, bioassay for evaluation of)

IT Cosmetics
 (moisturizers, irritancy of, for skin or eye, bioassay for evaluation of)

IT Hair preparations
 (straighteners, irritancy of, for skin or eye, bioassay for evaluation of)

IT Skin
 (stratum corneum, **keratinocyte** or fibroblast without, in bioassay for irritant evaluation)

IT Sunburn and Suntan
 (suntanning agents, irritancy of, for skin or eye, bioassay for evaluation of)

IT Hair preparations
 (wave-setting, irritancy of, for skin or eye, bioassay for evaluation of)

IT 298-93-1, MTT
 RL: ANST (Analytical study)
 (cell viability detn. with, in evaluation of irritants of skin or eye)

IT 1305-62-0, Calcium hydroxide, biological studies 1310-73-2,
 Sodium hydroxide, biological studies
 RL: BIOL (Biological study)
 (irritancy of, for skin or eye, bioassay for evaluation of)

IT 363-24-6, PGE2 9001-60-9, Lactate dehydrogenase
 RL: PROC (Process)
 (release of, from cultured cell, in evaluation of irritants of skin or eye)

IT 1305-62-0, Calcium hydroxide, biological studies
 RL: BIOL (Biological study)
 (irritancy of, for skin or eye, bioassay for evaluation of)

RN 1305-62-0 HCAPLUS
 CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)

HO—Ca—OH

L30 ANSWER 22 OF 27 HCAPLUS COPYRIGHT 2002 ACS
 AN 1992:158564 HCAPLUS
 DN 116:158564
 TI Hair dyeing composition containing
 5,6-dihydroxyindoline derivatives
 IN Lagrange, Alain; Luppi, Bernadette; Junino, Alex
 PA Oreal S. A., Fr.
 SO Eur. Pat. Appl., 18 pp.
 CODEN: EPXXDW
 DT Patent
 LA French
 IC ICM A61K007-13
 ICS C07D209-08; D06P001-32; D06P003-08; D06P003-30
 CC 62-3 (Essential Oils and **Cosmetics**)
 Section cross-reference(s): 27


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 462857	A1	19911227	EP 1991-401399	19910530
	EP 462857	B1	19940817		
	EP 462857	B2	19980304		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE

FR 2662701	A1	19911206	FR 1990-6803	19900531
FR 2662701	B1	19970718	AU 1991-78012	19910530
AU 9178012	A1	19911205		
AU 641605	B2	19930923		
ZA 9104148	A	19920325	ZA 1991-4148	19910530
ES 2057809	T3	19941016	ES 1991-401399	19910530
CA 2043672	AA	19911201	CA 1991-2043672	19910531
CN 1056874	A	19911211	CN 1991-103575	19910531
CN 1047592	B	19991222		
JP 04227974	A2	19920818	JP 1991-129400	19910531
JP 2997564	B2	20000111		
US 5178637	A	19930112	US 1991-707130	19910531
PRAI FR 1990-6803	A	19900531		
OS MARPAT 116:158564				
GI				

HO.



AB A hair dye compn. contains 5,6-dihydroxyindoline (I; R = H, C1-4 alkyl) and acid addn. salts therefrom. Bromohydric acid was reacted with 5,6-dimethoxyindoline followed by hydrolysis to obtain 5,6-dihydroxyindoline hydrobromide (II). A hair dye contg. II 2.0, ETOH 15.0, KI 1.0, preservatives q.s. and water 100.0 g was applied on 90% gray hair for 15 min followed by washing and application of a soln. contg. H2O2 at pH = 3 to get a dark brown color.

ST hair dye prepn indoline deriv

IT Named reagents and solutions

RL: BIOL (Biological study)
(Fenton's, hair dye compn. contg. dihydroxyindoline deriv. and)

IT Hair preparations
(dyes, dihydroxyindoline derivs. in)

IT Rare earth metals, compounds
RL: BIOL (Biological study)
(salts, hair dye compn. contg. dihydroxyindoline deriv. and)

IT 26602-89-1, Bromobutane
RL: RCT (Reactant)
(butylation by, of dimethoxyindole deriv.)

IT 15937-13-0 29539-03-5, 5,6-Dihydroxyindoline 138937-28-7 139721-20-3
139721-21-4 139721-22-5
RL: BIOL (Biological study)
(hair dye compn. contg.)

IT 7681-52-9, Sodium hypochlorite 7697-37-2D, Nitric acid, alkali metal and alk. earth metal salts. 7722-84-1, Hydrogen peroxide (H2O2),
miscellaneous 10294-54-9, Cesium sulfate 13444-71-8, Periodic acid 13444-71-8D, Periodic acid, salts 13465-41-3, Permanganic acid (HMnO4) 13746-66-2, Potassium ferricyanide 13907-47-6, Bichromate 20667-12-3, Silver oxide
RL: BIOL (Biological study)
(hair dye compn. contg. dihydroxyindoline deriv. and)

IT 106-51-4, 2,5-Cyclohexadiene-1,4-dione, miscellaneous 106-51-4D,
 2,5-Cyclohexadiene-1,4-dione, imine derivs. 127-52-6, Chloramine B
 127-65-1, Chloramine T 130-15-4, 1,4-Naphthoquinone 130-15-4D,
 1,4-Naphthoquinone, imine derivs. 524-42-5, 1,2-Naphthoquinone
 524-42-5D, 1,2-Naphthoquinone, imine derivs. 583-63-1,
 3,5-Cyclohexadiene-1,2-dione 583-63-1D, 3,5-Cyclohexadiene-1,2-dione,
 imine derivs. 1309-60-0, Lead oxide 7429-91-6, Dysprosium,
 miscellaneous 7439-89-6D, Iron, salts 7439-91-0, **Lanthanum**,
 miscellaneous 7439-96-5, Manganese, miscellaneous 7440-22-4D, Silver,
 salts 7440-45-1D, Cerium, salts 7440-48-4D, Cobalt, salts
 7440-50-8D, Copper, salts 7440-53-1, Europium, miscellaneous
 7440-54-2, Gadolinium, miscellaneous 7440-64-4, Ytterbium, miscellaneous
 7783-20-2, Ammonium sulfate, miscellaneous
 RL: MSC (Miscellaneous)
 (hair dye compn. contg. dihydroxyindoline deriv.
 and)

IT 7681-11-0, Potassium iodide, miscellaneous 7758-99-8, Copper sulfate
 pentahydrate 7790-28-5, Sodium metaperiodate
 RL: BIOL (Biological study)
 (hair dye prepn. contg. dihydroxyindoline deriv. and)

IT 139721-23-6P
 RL: RCT (Reactant); PREP (Preparation)
 (prepn. and hydrolysis of)

IT 139721-24-7P 139721-25-8P
 RL: PREP (Preparation)
 (prepn. of, for hair dye prepn.)

IT 15937-07-2, 5,6-Dimethoxyindoline
 RL: RCT (Reactant)
 (reaction of, with bromhydric acid)


IT 68890-32-4
 RL: RCT (Reactant)
 (reaction of, with bromic acid)

IT 7789-31-3, Bromic acid
 RL: RCT (Reactant)
 (reaction of, with dimethoxyindoline deriv.)

IT 13465-41-3, Permanganic acid (HMnO₄)
 RL: BIOL (Biological study)
 (hair dye compn. contg. dihydroxyindoline deriv.
 and)

RN 13465-41-3 HCAPLUS

CN Permanganic acid (HMnO₄) (7CI, 8CI, 9CI) (CA INDEX NAME)



L30 ANSWER 23 OF 27 HCAPLUS COPYRIGHT 2002 ACS
 AN 1990:446095 HCAPLUS
 DN 113:46095
 TI Phase-stable hair relaxer cream
 IN Akhtar, Muhammad M.; Newell, Florine
 PA Johnson Products Co., Inc., USA
 SO PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DT Patent

LA English

IC ICM A61K007-09

ICS A45D007-00

CC 62-3 (Essential Oils and Cosmetics)

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8909048	A1	19891005	WO 1989-US1199	19890323
	W: BB, BR RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	CA 1329368	A1	19940510	CA 1989-594236	19890320
	EP 362355	A1	19900411	EP 1989-904433	19890323
	EP 362355	B1	19950510		
	R: BE, DE, FR, GB, IT, NL				
	BR 8907336	A	19910326	BR 1989-7336	19890323
	US 5068101	A	19911126	US 1990-486538	19900228
	US 5171565	A	19921215	US 1991-778570	19911017
	US 5376364	A	19941227	US 1991-785095	19911030
PRAI	US 1988-173318		19880325		
	WO 1989-US1199		19890323		
	US 1989-399385		19890825		
	US 1989-410803		19890922		
	US 1990-486538		19900228		

AB The title **compn.** is a highly alk. and a no-base (or no-lye) cream that can be converted for use as a **hair relaxer** by admixing with an aq. activator soln. The **compn.** contains an alk. compd., such as alkali metal hydroxide or alk. earth hydroxide in oil-in-water emulsion base. Thus, a oil phase contg. petrolatum 15, white mineral oil 12, polawax 0.25, emulsifying wax 8, and Merquat 100 2 wt.% was placed in a mixer, heated to .apprx.80.degree. and mixed for .apprx.30 min. A water phase contg. deionized water q.s., Ca(OH)2 6.3, Mirano P DM 0.37, and propylene glycol 5 wt.% (preheated at .apprx.80.degree. for .apprx.15 min) was then added slowly to the oil phase while maintaining at .apprx.80.degree.. The resulting emulsion was stirred for 30-45 min and cooled to 55-45.degree., at which point perfume was added. The emulsion was again mixed for .apprx.15 min and cooled to give a smooth cream.

ST **hair relaxer** cream calcium hydroxide

IT Thickening agents

Paraffin oils

Petrolatum

RL: BIOL (Biological study)

(hair relaxer cream contg. alkali metal hydroxide and, phase-stable)

IT Alkali metal hydroxides

RL: BIOL (Biological study)

(hair relaxer cream contg., phase-stable)

IT Lanolin

RL: BIOL (Biological study)

(ethoxylated, hair relaxer cream contg. alkali metal hydroxide and, phase-stable)

IT Fatty acids, esters

RL: BIOL (Biological study)

(ethoxylated, esters, hair relaxer cream contg. alkali metal hydroxide and, phase-stable)

IT Alcohols, biological studies

RL: BIOL (Biological study)

(fatty, hair relaxer cream contg. alkali metal hydroxide and, phase-stable)

IT Alcohols, biological studies

RL: BIOL (Biological study)
(polyhydric, **hair relaxer** cream contg. alkali metal hydroxide and, phase-stable)

IT Hair preparations
(**relaxers**, alkali compds. and surfactants and conditioners in)

IT 50-70-4, Sorbitol, biological studies 50-70-4D, Sorbitol, fatty acid esters 56-81-5, Glycerin, biological studies 57-55-6, Propylene glycol, biological studies 107-41-5, Hexylene glycol 9003-11-6 25265-75-2, Butylene glycol 27299-12-3 28301-34-0D, salts 28603-06-7 30473-39-3 76689-43-5, Bentone Gel MIO

RL: BIOL (Biological study)
(**hair relaxer** cream contg. alkali metal hydroxide and, phase-stable)

IT 1305-62-0, Calcium hydroxide, biological studies 100224-74-6, Guanidine carbonate

RL: BIOL (Biological study)
(**hair relaxer** cream contg., phase-stable)

IT 1305-62-0, Calcium hydroxide, biological studies

RL: BIOL (Biological study)
(**hair relaxer** cream contg., phase-stable)

RN 1305-62-0 HCPLUS

CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)

HO—Ca—OH

L30 ANSWER 24 OF 27 HCPLUS COPYRIGHT 2002 ACS
AN 1982:187101 HCPLUS
DN 96:187101
TI Guanidine hydroxide **composition** for waving hair
IN De la Guardia, Mario J.
PA Carson Products Co., USA
SO Can., 51 pp. Division of Can. Appl. No. 318,443.
CODEN: CAXXA4
DT Patent
LA English
IC A61K007-09
CC 62-3 (Essential Oils and **Cosmetics**)
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION-NO.	DATE
PI	CA 1117423	A2	19820202	CA 1981-372184	19810303
	BR 7808756	A	19810630	BR 1978-8756	19781115
	CA 1106288	A1	19810804	CA 1978-318443	19781221
PRAI	CA 1978-318443		19781221		
	US 1977-805149		19770609		
	WO 1978-US157		19781115		

AB Human **hair straightening** or **relaxing compns**
. which exhibit improved **hair** strength retention and significantly decreased scalp irritation consist of guanidine hydroxide (I) [64120-25-8] (1.25-50% by wt.) as the principal active ingredient. These **compns.** exhibit permanent **relaxation** which lasts until new **hair** growth requires the repetition of treatment. I is freshly prep'd. from a mixt. contg. at least 1 water-sol. hydroxide such as Ca(OH)2 or Ba(OH)2 and 1 water-sol. guanidine salt, the anion of which forms a substantially water-insol. salt with the cation of the hydroxide in an aq. medium. A **hair relaxer** 2-component system

was formulated with 1 component being in the form of a cream emulsion contg. cetomacrogol wax 10, cetyl alc. 2.5, mineral oil 20, propylene glycol 5, Ca(OH)2 7.2% and H2O to 100%. This cream was mixed with a 25% aq. soln. of guanidine carbonate [593-85-1] in a ratio of 75:25 for 2 min. The hair of an individual was treated with this formulation for 20 min and washed with warm water and the hair neutralized with a neutralizing shampoo (pH 6.5) contg. triethanolamine lauryl sulfate 15, Na2HPO4 1.15, NaOH 0.093 and preservatives 0.35% (by wt.) and water to 100%. The hair treated had a permanent relaxing or straightening effect.

ST hair straightener guanidine hydroxide; calcium hydroxide guanidine carbonate hair; strontium hydroxide guanidine carbonate hair; barium hydroxide guanidine carbonate hair

IT Hair preparations
(straighteners, guanidine hydroxide for)

IT 64120-25-8
RL: BIOL (Biological study)
(hair straightener **compns.** contg.)

IT 593-85-1 594-14-9
RL: BIOL (Biological study)
(hair straightener **compns.** contg. alk. earth metal hydroxides and)

IT 1305-62-0, biological studies 17194-00-2
18480-07-4

RL: BIOL (Biological study)
(hair straightener **compns.** contg. water-sol. guanidine salts and)

IT 1305-62-0, biological studies 17194-00-2
18480-07-4

RL: BIOL (Biological study)
(hair straightener **compns.** contg. water-sol. guanidine salts and)

RN 1305-62-0 HCAPLUS

CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)

HO—Ca—OH

RN 17194-00-2 HCAPLUS
CN Barium hydroxide (Ba(OH)2) (9CI) (CA INDEX NAME)

HO—Ba—OH

RN 18480-07-4 HCAPLUS
CN Strontium hydroxide (Sr(OH)2) (9CI) (CA INDEX NAME)

HO—Sr—OH

L30 ANSWER 25 OF 27 HCAPLUS COPYRIGHT 2002 ACS
AN 1979:598794 HCAPLUS
DN 91:198794
TI Hairdressing **composition**
IN De la Guardia, Mario

PA Carson Products Co., USA
 SO Fr. Demande, 35 pp.
 CODEN: FRXXBL
 DT Patent
 LA French
 IC A61K007-09
 CC 62-3 (Essential Oils and Cosmetics)
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2393572	A1	19790105	FR 1978-16029	19780530
	FR 2393572	B1	19821105		
	GB 1600807	A	19811021	GB 1978-20877	19780519
	ZA 7803133	A	19790530	ZA 1978-3133	19780601
	WO 8001038	A1	19800529	WO 1978-US157	19781115
	W: BR, MG, MW RW: CF, CG, CM, GA, SN, TD, TG BR 7808756	A	19810630	BR 1978-8756	19781115
PRAI	US 1977-805149		1977-0609		
	WO 1978-US157		19781115		

AB A hair straightening compn. contains guanidine hydroxide [64120-25-8] as the active agent. The guanidine hydroxide is generated in situ by treating a guanidine salt with an alk. earth hydroxide. Thus, a straightening cream was prep'd. by mixing 25% aq. guanidine carbonate [593-85-1] into a cream consisting of Cetomacrogol 10, cetyl alc. 2.5, mineral oil 20, propylene glycol 5, Ca(OH)2 7.2, and H2O to 100%. After straightening the hair was washed with an acid shampoo contg. triethanolamine lauryl sulfate 15, NaH2PO4 1.15, NaOH 0.093, preservative 0.035, and H2O to 100%, pH 6.5.

ST hair straightening guanidine hydroxide

IT Hair preparations

(straightening compns., guanidine hydroxide in)

IT 1305-62-0, biological studies

RL: BIOL (Biological study)

(hair straightening compn. contg. guanidine carbonate and)

IT 64120-25-8

RL: BIOL (Biological study)

(hair straightening compns. contg.)

IT 593-85-1 594-14-9

RL: BIOL (Biological study)

(hair straightening compns. contg. alk. earth hydroxides and)

IT 17194-00-2 18480-07-4

RL: BIOL (Biological study)

(hair straightening compns. contg. guanidine carbonate and)

IT 1305-62-0, biological studies

RL: BIOL (Biological study)

(hair straightening compn. contg. guanidine carbonate and)

RN 1305-62-0 HCPLUS

CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)

HO—Ca—OH

IT 17194-00-2 18480-07-4

RL: BIOL (Biological study)

(hair straightening compns. contg. guanidine carbonate and)

RN 17194-00-2 HCAPLUS

CN Barium hydroxide (Ba(OH)2) (9CI) (CA INDEX NAME)

HO—Ba—OH

RN 18480-07-4 HCAPLUS

CN Strontium hydroxide (Sr(OH)2) (9CI) (CA INDEX NAME)

HO—Sr—OH

L30 ANSWER 26 OF 27 HCAPLUS COPYRIGHT 2002 ACS

AN 1976:578821 HCAPLUS

DN 85:178821

TI Contribution to the kinetics of **keratin** disulfide bond breaking in alkaline medium

AU Galatik, A.; Blazej, A.

CS Dep. Chem. Technol., Slovak Inst. Technol., Bratislava, Czech.

SO Collect. Czech. Chem. Commun. (1976), 41(8), 2289-95

CODEN: CCCCCAK

DT Journal

LA English

CC 39-3 (Textiles)

AB The kinetics of the disulfide bond breaking in wool **keratin** in aq. of NaOH, Ca(OH)2, and Na2S were detd. by the stress **relaxation** technique in oxygen-free medium, and chem. **relaxation** times and activation parameters were detd. The reaction in aq. Na2S was of the SN2 type. In aq. hydroxides, the predominating mechanism changed from elimination to SN2 when the alky. was >0.5M and the temp. was greater than the transition temp. of wool **keratin**.

ST wool **keratin** disulfide bond breaking; kinetics disulfide bond breaking; alkali disulfide bond breaking; mechanism disulfide bond breaking

IT Bond

(breaking of disulfide, of **keratin** in alkaline medium)

IT **Keratins**

RL: PRP (Properties)

(disulfide bonds of, breaking of, in alk. medium, kinetics and mechanism of)

IT Disulfide group

(in wool **keratin**, breaking of, in alkali, kinetics and mechanism of)

IT Kinetics, reaction

(of disulfide bond breaking, in **keratin** in alkaline medium)

IT 1305-62-0 1310-73-2, uses and miscellaneous 1313-82-2

RL: USES (Uses)

(**keratin** disulfide bond breaking in aq., kinetics and mechanism of)

IT 1305-62-0

RL: USES (Uses)

(**keratin** disulfide bond breaking in aq., kinetics and mechanism of)

RN 1305-62-0 HCAPLUS

CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)

HO—Ca—OH

L30 ANSWER 27 OF 27 HCPLUS COPYRIGHT 2002 ACS
AN 1970:436613 HCPLUS
DN 73:36613
TI Action of unhairing agents on wool **keratin**
AU Simoncini, Alberto; Del Pezzo, Luigi; Manzo, G.
CS Sta. Sper. Ind. Pelli Mater. Conciante, Naples, Italy
SO Cuoio, Pelli, Mater. Conciante (1969), 45(6), 649-64
CODEN: CPMAAJ
DT Journal
LA Italian
CC 41 (Leather and Related Materials)
AB By using ir spectrophotometry, the mechanism of the action of alk. solns. of Na₂S, Me₂NH and Ca(OH)₂ on wool **keratin** was studied. With amines, the products formed due to the rupture of the S-S bond were oxidized to sulfinic acid, which, on reacting with NH₂ groups, formed sulfinamides. With Na₂S, the sulfonium ions reacted with the NaS-, forming compds. of the RSSNa type (where R is a protein residue). The action of lime on **keratin** for short periods, formed compds. of the ester type. In all cases, the formation of **lanthionine** was noticed.
ST wool **keratin** unhairing; **keratin** wool unhairing; unhairing wool jeratin; sodium sulfide wool **keratin**; dimethylamine wool **keratin**; calcium hydroxide wool **keratin**; lime action wool **keratin**; sulfinamides formation; **lanthionine** formation
IT Spectrophotometry
(infrared, of wool **keratins** in hide unhairing)
IT Wool
(**lanthionine** formation in, in presence of unhairing agents)
IT **Keratins**
RL: USES (Uses)
(reactions of wool, with unhairing agents)
IT Hides
(unhairing of sheepskins, reactions of wool **keratins** in)
IT 496-98-0P
RL: FORM (Formation, nonpreparative); PREP (Preparation)
(formation of, wool **keratin** reaction with unhairing agents in relation to)
IT 1305-62-0 1313-82-2
RL: RCT (Reactant)
(reaction of, with wool **keratins**, in hide unhairing)
IT 124-40-3, reactions
RL: RCT (Reactant)
(with wool **keratins**, in hide unhairing)
IT 1305-62-0
RL: RCT (Reactant)
(reaction of, with wool **keratins**, in hide unhairing)
RN 1305-62-0 HCPLUS
CN Calcium hydroxide (Ca(OH)₂) (9CI) (CA INDEX NAME)

HO—Ca—OH

=> d que

L4 4 SEA FILE=REGISTRY ABB=ON CALCIUM HYDROXIDE/CN OR BARIUM HYDROXIDE/CN OR MAGNESIUM HYDROXIDE/CN OR ALUMINUM HYDROXIDE/CN

L5 1 SEA FILE=REGISTRY ABB=ON "CUPRIC HYDROXIDE"/CN

L6 6 SEA FILE=REGISTRY ABB=ON STRONTIUM HYDROXIDE/CN OR MOLYBDENUM HYDROXIDE/CN OR MANGANESE HYDROXIDE/CN OR ZINC HYDROXIDE/CN OR COBALT HYDROXIDE/CN

L7 11 SEA FILE=REGISTRY ABB=ON (L4 OR L5 OR L6)

L8 1515 SEA FILE=REGISTRY ABB=ON ((CA OR BA OR MG OR AL OR CU OR SR OR MO OR MN OR ZN OR CO) (L)O(L)H) /ELS(L)3/ELC.SUB

L9 48595 SEA FILE=HCAPLUS ABB=ON L7

L10 100 SEA FILE=HCAPLUS ABB=ON L9 AND (HAIR OR KERAT?)

L11 2 SEA FILE=HCAPLUS ABB=ON L10 AND LANTHION?

L13 12 SEA FILE=HCAPLUS ABB=ON L10 AND RELAX?

L15 61496 SEA FILE=HCAPLUS ABB=ON L8

L16 112 SEA FILE=HCAPLUS ABB=ON L15 AND (HAIR OR KERAT?)

L17 13 SEA FILE=HCAPLUS ABB=ON L16 AND (RELAX? OR LANTHIO?)

L18 13 SEA FILE=HCAPLUS ABB=ON L11 OR L13 OR L17

L19 112 SEA FILE=HCAPLUS ABB=ON L10 OR L16

L20 55 SEA FILE=HCAPLUS ABB=ON L19 AND (COMPOSITION? OR COMPNS)

L21 34 SEA FILE=HCAPLUS ABB=ON L20 AND COSMETIC?/SC, SX

L22 40 SEA FILE=HCAPLUS ABB=ON L20 AND (HAIR OR KERAT? (3A) FIBER?)

L23 30 SEA FILE=HCAPLUS ABB=ON L21 AND L22

L24 11 SEA FILE=HCAPLUS ABB=ON L23 AND (RELAX? OR RELEAS? OR LANTH?)

L27 17 SEA FILE=HCAPLUS ABB=ON L21 AND HYDROXIDES/IT

L28 24 SEA FILE=HCAPLUS ABB=ON L18 OR L24 OR L27

L29 4 SEA FILE=HCAPLUS ABB=ON L20 AND COMPLEX?

L30 27 SEA FILE=HCAPLUS ABB=ON L28 OR L29

L31 11 SEA FILE=HCAPLUS ABB=ON L19 AND STRAIGHT?

L32 4 SEA FILE=HCAPLUS ABB=ON (L30 OR L31) NOT L30

=> d 132 all 1-4 hitstr

L32 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2002 ACS
 AN 2000:768952 HCAPLUS
 DN 133:339965
 TI Formulations and methods for reducing skin irritation
 IN Hahn, Gary S.; Thueson, David O.
 PA Cosmederm Technologies, USA
 SO U.S., 30 pp., Cont.-in-part of U.S. 5,716,625.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM A61K007-48
 NCL 424401000
 CC 62-4 (Essential Oils and Cosmetics)
 Section cross-reference(s): 63

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6139850	A	20001031	US 1997-860993	19970623
	US 5716625	A	19980210	US 1994-362100	19941221
	WO 9619184	A1	19960627	WO 1995-US16985	19951221
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD,				

MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ,
TM, TT

RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR,
NE, SN, TD, TG

EP 1136065 A1 20010926 EP 2001-115074 19951221

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE

PRAI US 1994-362100 A2 19941221

WO 1995-US16985 W 19951221

EP 1995-944548 A3 19951221

AB Compns. and methods are provided for inhibiting skin irritation attributable to chem. irritants or environmental conditions, by the application of an anti-irritant amt. of water-sol. strontium cation. The compns. can be antiperspirants, deodorants, sunscreens, insect repellents, depilatories, hair dyes, hair bleaches, mouthwashes, ointments, suppositories, etc. Glycolic acid (6 % in 10 % ethanol-in-water) was used as a skin irritant. Strontium nitrate was coadministered as an anti-irritant to subject panels and was shown to inhibit cumulative irritation by 64-84 % at concns. ranging from 250 nM to 500 nM.

ST strontium compd skin irritation prevention

IT Essential oils

RL: ADV (Adverse effect, including-toxicity); THU--(Therapeutic use); BiOL
(Biological study); USES (Uses)

(Melaleuca; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Shaving preparations

(aftershave; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Hair preparations

(antidandruff; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Skin preparations (pharmaceutical)

(astringents; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Dermatitis

(atopic; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Hair preparations

(bleaches; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Ion channel blockers

(calcium; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Cosmetics

(cleansing; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Temperature

(cold; strontium compds. for reducing skin irritation due to environmental conditions)

IT Hair preparations

(conditioners; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Eye, disease

(conjunctivitis; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Cosmetics

(creams; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Cosmetics

(depilatories; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Digestive tract
Mucous membrane
Reproductive tract
(disease, irritations; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Bath preparations
(douches; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Skin, disease
(dry; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Hair preparations
(dyes; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Drug delivery systems
(enemas; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Aloe barbadensis
Chamomile
Cola nitida
(exts.; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Tea products
(green, exts.; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Carboxylic acids, biological studies
RL: ADV (Adverse effect, including toxicity); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hydroxy; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Acne
(inhibitors; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Eye, disease
Respiratory tract
Skin, disease
(irritation; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Fatty acids, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lanolin, strontium salts; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Natural products, pharmaceutical
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(licorice; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Cosmetics
(lotions; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Drug delivery systems
(lozenges; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Cosmetics
(moisturizers; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Anti-inflammatory agents

(nonsteroidal; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Drug delivery systems
(ointments; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Drug delivery systems
(ophthalmic; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Carboxylic acids, biological studies
RL: ADV (Adverse effect, including toxicity); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(oxo; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Hair preparations
(permanent wave; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Ion channel blockers
(potassium; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Nose
(rhinitis; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Ion channel blockers
(sodium; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Hair preparations
(straighteners; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Solar radiation
Wind
(strontium compds. for reducing skin irritation due to environmental conditions)

IT Analgesics
Antibiotics
Antiperspirants
Asthma
Contraceptives
Deodorants
Dermatitis
Detergents
Eczema
Infection
Insect repellents
Mouthwashes
Psoriasis
Shampoos
Shaving preparations
Sunscreens
(strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Alcohols, biological studies
Carboxylic acids, biological studies
Peroxides, biological studies
Retinoids
Soaps
RL: ADV (Adverse effect, including toxicity); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Steroids, biological studies

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Caseins, biological studies
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(strontium salts; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Drug delivery systems
(suppositories, vaginal; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Drug delivery systems
(suppositories; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT Drug delivery systems
(topical; strontium compds. for reducing skin irritation due to ingredients in compns.)

IT 50-21-5, Lactic acid, biological studies 57-13-6, Urea, biological studies 58-08-2, Caffeine, biological studies 64-19-7, Acetic acid, biological studies 68-26-8, Retinol 69-72-7, biological studies 76-03-9, Trichloroacetic acid, biological studies 76-93-7, biological studies 77-92-9, biological studies 79-14-1, biological studies 87-69-4, biological studies 90-64-2, Mandelic acid 90-80-2 94-36-0, Benzoyl peroxide, biological studies 97-59-6, Allantoin 98-79-3 108-95-2, Phenol, biological studies 116-31-4, Retinal 127-17-3, Pyruvic acid, biological studies 144-62-7, Ethanedioic acid, biological studies 302-79-4, Tretinoin 404-86-4, Capsaicin. 515-69-5, .alpha.-Bisabolol 526-95-4, D-Gluconic acid 617-73-2, .alpha.-Hydroxy octanoic acid 1405-86-3, Glycyrrhizic acid 5393-81-7, .alpha.-Hydroxy decanoic acid 6915-15-7 70424-62-3 126094-21-1
RL: ADV (Adverse effect, including toxicity); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(strontium compds. for reducing skin irritation due to ingredients in compns.)

IT 526-26-1, Strontium salicylate 543-94-2, Strontium acetate 592-89-2, Strontium formate 813-97-8 814-95-9, Strontium oxalate 868-19-9, Strontium tartrate, biological studies 1314-11-0, Strontium oxide, biological studies 1314-18-7, Strontium peroxide 1314-96-1, Strontium sulfide 1633-05-2, Strontium carbonate 2188-25-2, Strontium benzoate 7100-64-3, Strontium bicarbonate 10042-76-9, Strontium nitrate 10101-21-0, Strontium gluconate 10196-69-7, Strontium stearate 10476-85-4, Strontium chloride 12060-59-2, Strontium titanate 13451-01-9, Strontium bisulfate 13470-06-9, Strontium nitrite 13703-84-9, Strontium borate 14796-93-1, Strontium laurate 14796-94-2, Strontium myristate 14796-95-3, Strontium palmitate 14987-70-3, Strontium behenate 15578-33-3 16088-89-4 17006-00-7
18480-07-4, Strontium hydroxide 23287-50-5, Strontium propionate 29870-99-3, Strontium lactate 39162-74-8 40472-00-2 59039-08-6, Strontium oleate 59640-09-4, Strontium phthalate 63387-34-8, Strontium thioglycolate 74563-70-5 88092-77-7 139965-15-4 303730-87-2 303730-88-3 303730-89-4 303730-90-7 303730-91-8 303730-92-9 304006-79-9 304006-80-2
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(strontium compds. for reducing skin irritation due to ingredients in compns.)

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; FR 2590273 1987 HCAPLUS

(2) Anon; EP 0654270 1995 HCPLUS
 (3) Anon; The Merck Index, 11th Ed 1989, P1394
 (4) Biener; US 4943432 1990 HCPLUS
 (5) Bilotto; Pain 1988, V32, P231 HCPLUS
 (6) Breton; US 5851556 1998 HCPLUS
 (7) Celerier; Arch Dermatol Res 1985, V287, P680
 (8) Chess; US 4971800 1990 HCPLUS
 (9) de Lacharriere; US 5824650 1998 HCPLUS
 (10) de Lacharriere; US 5866168 1999 HCPLUS
 (11) de Lacharriere; US 5972892 1999 HCPLUS
 (12) D'Alelio; US 4477439 1984 HCPLUS
 (13) Edwards; US 4285973 1981 HCPLUS
 (14) Foreman, J; J Physiol 1977, V271, P233 HCPLUS
 (15) Frankenhaeuser; J Physiol 1958, V142, P360 HCPLUS
 (16) Gutentag; Penn Dental Journal 1965, V68(2), P37 MEDLINE
 (17) Hahn; US 5716625 1998 HCPLUS
 (18) Hahn; US 5804203 1998 HCPLUS
 (19) Hodosh; US 4191750 1980 HCPLUS
 (20) Klein; US 4388301 1983 HCPLUS
 (21) Mishima; US 5262153 1993 HCPLUS
 (22) Porter; US 3716054 1973
 (23) Yu; US 4105782 1978 HCPLUS
 (24) Yu; US 4105783 1978
 (25) Zyuzukin, Y; 1973, 12, P100 HCPLUS

IT 18480-07-4, Strontium hydroxide
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)-
 (strontium compds. for reducing skin irritation due to ingredients in
 compns.)

RN 18480-07-4 HCPLUS
 CN Strontium hydroxide (Sr(OH)2) (9CI) (CA INDEX NAME)

HO—Sr—OH .

L32 ANSWER 2 OF 4 HCPLUS COPYRIGHT 2002 ACS
 AN 1997:257488 HCPLUS
 DN 126:242597
 TI Improved hair-straightening emulsion containing
 alkaline earth hydroxide
 IN Darkwa, Adu Gyamfi; Villanueva, Apolonio Iii
 PA Johnson Products Co., Inc., USA
 SO PCT Int. Appl., 93 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K007-07
 CC 62-3 (Essential Oils and Cosmetics)
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9707775	A1	19970306	WO 1996-US13606	19960822
W: BR, CA, GB, MX				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5679327	A	19971021	US 1995-519287	19950825
CA 2230224	AA	19970306	CA 1996-2230224	19960822
GB 2319787	A1	19980603	GB 1998-3520	19960822

GB 2319787 B2 19990825
PRAI US 1995-519287 19950825
WO 1996-US13606 19960822

AB An improved highly alk. hair-straightening emulsion and a 2-component system for prep. the emulsion are provided. The emulsion employs a combination of strong nitrogenous org. base and alkali metal hydroxide in the presence of an alk. earth metal cation, preferably with addn. of a quaternary ammonium conditioner. Neither the amt. of the alkali metal hydroxide nor the amt. of org. base present in the emulsion is sufficient by itself to effectively permanently **straighten** naturally curly hair. Alk. earth metal hydroxides are characteristically ineffective as permanent hair **straighteners**. However, the combination is effective for achieving permanent **straightening** of hair within a treatment time of .1toreq.30-min. The emulsion also substantially avoids scalp skin irritation and minimizes hair discoloration and hair breakage. Thus, a cream emulsion contg. petrolatum 15, mineral oil 10, cetearyl alc. 11, modified hectorite clay gellant 2, Miranol DM (amphoteric emulsifier) 0.5, ethoxylated lanolin 1.5, propylene glycol 5, Polyquaternium-6 (conditioner) 1.26, Ca(OH)2 2.5, LiOH.H2O 1.25, perfume, and H2O to 100 wt.% was converted to a hair-straightening emulsion by mixing 3.5-5 parts cream emulsion with 1 part liq. activator component contg. 10-20 wt.% guanidine carbonate.

ST hair straightening emulsion alkali alk earth; hydroxide alk earth hair straightening emulsion; nitrogenous base hair straightening emulsion

IT Quaternary ammonium compounds, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(conditioners; improved hair-straightening emulsion contg. alk. earth hydroxide)

IT Hair preparations
(emulsions; improved hair-straightening emulsion contg. alk. earth hydroxide)

IT Hair conditioners
(improved hair-straightening emulsion contg. alk. earth hydroxide)

IT Alkali metal hydroxides
Alkaline earth hydroxides
Bases, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(improved hair-straightening emulsion contg. alk. earth hydroxide)


IT Hair preparations
(straighteners; improved hair-straightening emulsion contg. alk. earth hydroxide)

IT 7727-37-9D, Nitrogen, org. compds.
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(bases; improved hair-straightening emulsion contg. alk. earth hydroxide)

IT 17301-53-0, Behenyltrimethylammonium chloride 26062-79-3, Polyquaternium-6 81646-13-1
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(conditioner; improved hair-straightening emulsion contg. alk. earth hydroxide)

IT 113-00-8, Guanidine 113-00-8D, Guanidine, derivs. 143-37-3, Acetamidine 143-37-3D, Acetamidine, derivs. 1305-62-0, Calcium

hydroxide (Ca(OH)2), biological studies 1310-58-3, Potassium hydroxide, biological studies 1310-65-2, Lithium hydroxide 1310-73-2, Sodium hydroxide, biological studies--64120-25-8 100224-74-6, Guanidine carbonate 188537-24-8
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (improved hair-straightening emulsion contg. alk. earth hydroxide)
 IT 1305-62-0, Calcium hydroxide (Ca(OH)2), biological studies
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (improved hair-straightening emulsion contg. alk. earth hydroxide)
 RN 1305-62-0 HCAPLUS
 CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)



L32 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2002 ACS
 AN 1983:39667 HCAPLUS
 DN 98:39667
 TI Orientation of hydration products near aggregate surfaces
 AU Grandet, J.; Ollivier, J. P.
 CS Dep. Gen. Civil, Univ. Paul Sabatier, Toulouse, Fr.
 SO Int. Congr. Chem. Cem., [Proc.], 7th (1980), Volume 3, VII/63-VII/68
 Publisher: SEPTIMA, Paris, Fr.
 CODEN: 48JWAH
 DT Conference
 LA French
 CC 58-1 (Cement, Concrete, and Related Building Materials)
 AB The oriented growth of portlandite crystals in the interfacial zone around aggregates, allowing the evolution of hair-line cracks, influences the mech. strength. The orientation of Ca(OH)2 crystals in portland cement paste hardening with different aggregates (quartz, polyethylene [9002-88-4], limestone) was studied. Successive sections of cement paste parallel to the contact interface were studied by x-ray diffraction. The curves $I = f(\log d)$ are then plotted, where I is an orientation index which is greater than 1 when the crystal is oriented and d is the distance between the contact interface and the analyzed section. I is >1 at distances up to d_0 , the so-called limit of orientation, and $I = f(\log d)$ is represented by a straight line. Beyond the distance d_0 , the portlandite crystals have no particular orientation. Among the parameters studied, the orientation limit of the portlandite crystals depended on the amt. of mixing water, d_0 increased with the water/cement ratio, and the slope of the curves [$I = f(\log d)$, for $(d < d_0)$] depended on the nature of the aggregate, the curing time, and the humidity of the storage medium. This slope characterizes the suitability of the aggregates to orient the portlandite crystals and their growth from the nucleus.
 ST portlandite crystal growth cement
 IT Limestone, uses and miscellaneous
 RL: USES (Uses)
 (cement aggregates, portlandite oriented crystal growth in relation to)
 IT Cement
 (portlandite oriented crystal growth in, aggregate effect on)
 IT 9002-88-4 14808-60-7, uses and miscellaneous
 RL: USES (Uses)

(cement aggregates, portlandite oriented crystal growth in relation to)
 IT 1305-62-0, properties
 RL: PRP (Properties)
 (crystal growth of, oriented, in cement, aggregate effect on)
 IT 1305-62-0, properties
 RL: PRP (Properties)
 (crystal growth of, oriented, in cement, aggregate effect on)
 RN 1305-62-0 HCPLUS
 CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)

HO—Ca—OH

L32 ANSWER 4 OF 4 HCPLUS COPYRIGHT 2002 ACS

AN 1980:135131 HCPLUS

DN 92:135131

TI Solid hair straightening product

IN Wajaroff, Theodor

PA Wella A.-G., Fed. Rep. Ger.

SO Ger. Offen., 12 pp.

CODEN: GWXXBX

DT Patent

LA German

IC A61K007-09

CC 62-3 (Essential Oils and Cosmetics)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2823243	A1	19791129	DE 1978-2823243	19780527
	ZA 7902312	A	19800528	ZA 1979-2312	19790514
	BR 7903210	A	19791211	BR 1979-3210	19790523

PRAI DE 1978-2823243 19780527

AB A solid hair straightening compn. contained a Ca or Sr oxide or hydroxide and a Li, Na, or K carbonate, hydrogen carbonate, sulfate, or phosphate, or a Li, Na, K alcoloholate together with thickeners and cosmetic additives. Thus, a mixt. of 10 g Ca(OH)2, 76.5 g kaolin, and 13.5 g Na2CO3 was mixed 1:1 with water at 35.degree. to form a paste.

ST hair straightening prepns powder

IT Hair preparations

(straighteners, powders)

IT 124-41-4 141-52-6

RL: BIOL (Biological study)

(hair straightening compn. contg.)

IT 18480-07-4 1305-62-0, uses and miscellaneous

1305-78-8, uses and miscellaneous 1314-11-0, uses and miscellaneous

RL: BIOL (Biological study)

(hair straightening compn. contg. carbonate and)

IT 7601-54-9 7757-82-6, uses and miscellaneous 144-55-8, uses and

miscellaneous 497-19-8, uses and miscellaneous 554-13-2

RL: BIOL (Biological study)

(hair straightening compn. contg. oxide or hydroxide and)

IT 18480-07-4 1305-62-0, uses and miscellaneous

RL: BIOL (Biological study)

(hair straightening compn. contg. carbonate and)

RN 18480-07-4 HCPLUS

CN Strontium hydroxide (Sr(OH)2) (9CI) (CA INDEX NAME)

HO—Sr—OH

RN 1305-62-0 HCAPLUS
CN Calcium hydroxide (Ca(OH)2) (9CI) (CA INDEX NAME)

HO—Ca—OH